<!DOCTYPE html>
<html>
<head>
    <style>
        .annotation-head {
            padding-top: 7px;
        }

        .annotation-segment, .annotation-head {
            position: relative;
        }

        .anno {
            position: relative;
            text-align: center;
        }

        .label {
            -webkit-border-radius: 3px;
            -moz-border-radius: 3px;
            border-radius: 3px;

            display: inline-block;
            padding: 2px 0;
            font-size: 11.844px;
            font-weight: bold;
            line-height: 14px;
            color: #000000;
            text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.25);
            white-space: nowrap;
            vertical-align: baseline;
            background-color: #999999;
        }

        .marker {
            background: lightgreen;
        }

        .collapsible {
            background-color: #929af0;
            color: #444;
            cursor: pointer;
            padding: 18px;
            width: 100%;
            border: none;
            text-align: left;
            outline: none;
            font-size: 15px;
        }

        .collapsible:hover {
            background-color: #ccc;
        }

        .midcontainer {
            overflow: hidden;
            overflow-x: auto;
            white-space: nowrap;
            margin: 10px;
        }
        .abstractcontainer {
            margin: 10px;
            line-height: 200%;
        }

        .supercontainer {
            border-style: solid;
	        border-width: 1px;
	        border-color: black;
        	border-radius: 3px;
            margin: 10px;
        }
    </style>
    <script src="http://ajax.googleapis.com/ajax/libs/jquery/1.4.1/jquery.min.js" type="text/javascript"></script>
    <script src="http://ajax.googleapis.com/ajax/libs/prototype/1.6.1.0/prototype.js" type="text/javascript"></script>
    <script src="http://ajax.googleapis.com/ajax/libs/scriptaculous/1.8.3/scriptaculous.js"
            type="text/javascript"></script>
    <script type="text/javascript">
        (function ($) {
            String.prototype.width = function (font) {

                var f = font || '12px arial',
                    o = $('<div>' + this + '</div>')
                        .css({
                            'position': 'absolute',
                            'float': 'left',
                            'white-space': 'nowrap',
                            'visibility': 'hidden',
                            'font': f
                        })
                        .appendTo($('body')),
                    w = o.width();

                o.remove();

                return w;
            }

            $(document).ready(function () {
                $('.container').each(function () {
                    var c = $(this);
                    $(c).find('.marker').each(function () {
                        var $t = $(this),
                            pos = $t.attr('data-anno-label'),
                            id = $t.attr('head-id'),
                            annoStr = pos;
                        var total_width = 0;
                        $(c).find('.annotation-head .anno').each(function () {
                            total_width += $(this).width();
                        })
                        // create an annotation for each marker
                        var top = this.offsetTop - 5,
                            left = this.offsetLeft - total_width,
                            width = $t.width(),
                            style = 'style="top:' + top + 'px; left:' + left + 'px;width:' + width + 'px;"';

                        $(c).find('.annotation-head').append('<span class="anno label" ' + style + '>' + annoStr + '</span>');
                    });
                })
            });
        })(jQuery);

    </script>
</head>

<body>


<button type="button" class="collapsible">AnnotatorA - AnnotatorB</button>
        <div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorA:</b>  Pegylated liposomal  <span class="marker" data-anno-id="0" data-anno-label="C1">doxorubicin</span>  plus  <span class="marker" data-anno-id="1" data-anno-label="C1">cyclophosphamide</span>  followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer : results of the phase II CAPRICE study . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorB:</b>  Pegylated liposomal  <span class="marker" data-anno-id="0" data-anno-label="P1">doxorubicin</span>  plus  <span class="marker" data-anno-id="1" data-anno-label="P1">cyclophosphamide</span>  followed by  <span class="marker" data-anno-id="2" data-anno-label="P1">paclitaxel</span>  as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer : results of the phase II CAPRICE study . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u><b style='color:DodgerBlue;'><i>Pegylated</i></b> <b style='color:DodgerBlue;'><i>liposomal</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>primary</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>elderly</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>cardiotoxicity-prone</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>high-risk</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>results</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>II</i></b> <b style='color:DodgerBlue;'><i>CAPRICE</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h4>Anthracycline and taxane-based primary chemotherapy (PCT) is the standard treatment for high-risk breast cancer (HRBC). However, conventional anthracyclines are not commonly used in elderly patients or those prone to cardiotoxicity. Pegylated liposomal <b style='color:Tomato;'><i>doxorubicin</i></b>, (PLD) has comparable efficacy, but less cardiotoxicity than conventional anthracyclines. We conducted a phase II single-arm trial to assess the efficacy and safety of PCT based on PLD followed by <b style='color:Tomato;'><i>paclitaxel</i></b> (PTX) in a HRBC population usually undertreated. Fifty patients with stage II-IIIB breast cancer and at least one risk factor for developing cardiotoxicity initiated PLD 35 mg/m(2) plus <b style='color:Tomato;'><i>cyclophosphamide</i></b> 600 mg/m(2) every 4 weeks for four cycles, followed by 80 mg/m(2) weekly PTX for 12. Close cardiac monitoring was performed. Primary endpoint was the pathological complete response rate (pCR) in the breast. Treatment delivery and toxicities were assessed. Eighty-four per cent of patients were older than 65 years, 64 % suffered from hypertension, and 10 % had prior cardiac disease. In an intention-to-treat analysis, breast pCR was 32 % (95 % CI 19.5-46.7 %) and pCR in breast and axilla was 24 % (95 % CI 12.1-35.8 %). At diagnosis only, 26 % of patients were candidates for breast conservative surgery, which increased to 58.7 % after PCT. No significant decrease in left ventricular ejection fraction was seen. PLD followed by PTX was feasible in a fragile population of patients who were not candidates for conventional <b style='color:Tomato;'><i>doxorubicin</i></b>. Moreover, it achieved a pCR similar to standard therapy and could therefore be an option for elderly patients or cardiotoxicity-prone who present HRBC.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorA:</b>  Dual Therapy with  <span class="marker" data-anno-id="0" data-anno-label="P1">Aspirin</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">Cilostazol</span>  May Improve Platelet Aggregation in Noncardioembolic Stroke Patients : A Pilot Study . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorB:</b>  Dual Therapy with  <span class="marker" data-anno-id="0" data-anno-label="C1">Aspirin</span>  and  <span class="marker" data-anno-id="1" data-anno-label="C1">Cilostazol</span>  May Improve Platelet Aggregation in Noncardioembolic Stroke Patients : A Pilot Study . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u><b style='color:DodgerBlue;'><i>Dual</i></b> <b style='color:DodgerBlue;'><i>Therapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>Aspirin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>Cilostazol</i></b> <b style='color:DodgerBlue;'><i>May</i></b> <b style='color:DodgerBlue;'><i>Improve</i></b> <b style='color:DodgerBlue;'><i>Platelet</i></b> <b style='color:DodgerBlue;'><i>Aggregation</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>Noncardioembolic</i></b> <b style='color:DodgerBlue;'><i>Stroke</i></b> <b style='color:DodgerBlue;'><i>Patients</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>Pilot</i></b> <b style='color:DodgerBlue;'><i>Study</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h4>Objective Some previous studies have found clinical benefit of dual antiplatelet therapy with <b style='color:Tomato;'><i>aspirin</i></b> and <b style='color:Tomato;'><i>cilostazol</i></b> for prevention of secondary stroke, but the physiological mechanism involved remains unknown. We aimed to clarify the effects of <b style='color:Tomato;'><i>aspirin</i></b>/<b style='color:Tomato;'><i>cilostazol</i></b> therapy on the platelet and endothelial functions of patients with acute noncardioembolic ischemic stroke, in comparison to patients who were treated with <b style='color:Tomato;'><i>aspirin</i></b> alone. Methods The present randomized prospective pilot study enrolled 24 patients within a week after the onset of noncardioembolic ischemic stroke. The patients were randomly allocated to receive <b style='color:Tomato;'><i>aspirin</i></b> (100 mg/day) (A group; 11 patients) or <b style='color:Tomato;'><i>cilostazol</i></b> (200 mg/day) plus <b style='color:Tomato;'><i>aspirin</i></b> (100 mg/day) (CA group; 13 patients). We measured platelet aggregation, platelet activation, and the thrombomodulin (TM), highly sensitive C-reactive protein (hs-CRP), intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and von Willebrand (vWF) antigen levels and vWF activity over a 4-week period after enrollment. Results There was no significant difference in the platelet functions of the A and CA groups. However, the platelet aggregation induced by adenosine diphosphate (ADP) was decreased at 2 and 4 weeks (p<0.05) after treatment in comparison to the pre-treatment values in the CA group, but not in the A group. Platelet activation, and the hs-CRP, TM, ICAM-1, VCAM-1 and vWF values did not significantly decrease after treatment in either group. Conclusion Although there were no significant differences in platelet aggregation, platelet activation or the endothelial biomarker levels of the A and CA groups, dual therapy with <b style='color:Tomato;'><i>aspirin</i></b> and <b style='color:Tomato;'><i>cilostazol</i></b> inhibited platelet aggregation in comparison to the pre-treatment values, similarly to patients who received <b style='color:Tomato;'><i>aspirin</i></b> alone. This may suggest the clinical usefulness of dual therapy with <b style='color:Tomato;'><i>aspirin</i></b> and <b style='color:Tomato;'><i>cilostazol</i></b> in the treatment of patients with noncardioembolic ischemic stroke.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorA:</b>  Once-weekly  <span class="marker" data-anno-id="0" data-anno-label="N1">isoniazid</span>  and  <span class="marker" data-anno-id="1" data-anno-label="N1">rifapentine</span>  for 3 months is a treatment option in persons with human immunodeficiency virus and latent tuberculosis infection . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorB:</b>  Once-weekly  <span class="marker" data-anno-id="0" data-anno-label="P1">isoniazid</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">rifapentine</span>  for 3 months is a treatment option in persons with human immunodeficiency virus and latent tuberculosis infection . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Cytokine-Mediated Systemic Adverse Drug Reactions in a Drug-Drug Interaction Study of Dolutegravir With Once-Weekly Isoniazid and Rifapentine.</u></h4> <b style='color:DodgerBlue;'><i>Once-weekly</i></b> <b style='color:MediumOrchid;'><i>isoniazid</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>rifapentine</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>months</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>option</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>persons</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>human</i></b> <b style='color:DodgerBlue;'><i>immunodeficiency</i></b> <b style='color:DodgerBlue;'><i>virus</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>latent</i></b> <b style='color:DodgerBlue;'><i>tuberculosis</i></b> <b style='color:DodgerBlue;'><i>infection</i></b> <b style='color:DodgerBlue;'><i>.</i></b> This study aimed to examine pharmacokinetic drug-drug interactions between this regimen and <b style='color:Tomato;'><i>dolutegravir</i></b>, a first-line antiretroviral medication. ### methods This was a single-center, open-label, fixed-sequence, drug-drug interaction study in healthy volunteers. Subjects received oral <b style='color:Tomato;'><i>dolutegravir</i></b> 50 mg once daily alone (days 1-4) and concomitantly with once-weekly <b style='color:Tomato;'><i>isoniazid</i></b> 900 mg, <b style='color:Tomato;'><i>rifapentine</i></b> 900 mg, and <b style='color:Tomato;'><i>pyridoxine</i></b> 50 mg (days 5-19). <b style='color:Tomato;'><i>dolutegravir</i></b> concentrations were measured on days 4, 14, and 19, and <b style='color:Tomato;'><i>rifapentine</i></b>, 25-desacetyl-<b style='color:Tomato;'><i>rifapentine</i></b>, and <b style='color:Tomato;'><i>isoniazid</i></b> concentrations were measured on day 19. Cytokines and antidrug antibodies to <b style='color:Tomato;'><i>isoniazid</i></b> and <b style='color:Tomato;'><i>rifapentine</i></b> were examined at select time points. ### results The study was terminated following the development of flu-like syndrome and elevated aminotransferase levels in 2 of 4 subjects after the third <b style='color:Tomato;'><i>isoniazid</i></b>-<b style='color:Tomato;'><i>rifapentine</i></b> dose. Markedly elevated levels of interferon-γ, CXCL10, C-reactive protein, and other cytokines were temporally associated with symptoms. Antidrug antibodies were infrequently detected. <b style='color:Tomato;'><i>dolutegravir</i></b> area under the curve (AUC) was decreased by 46% (90% confidence interval, 27-110%; P = .13) on day 14. <b style='color:Tomato;'><i>rifapentine</i></b> and 25-desacetyl <b style='color:Tomato;'><i>rifapentine</i></b> levels on day 19 were comparable to reference data, whereas <b style='color:Tomato;'><i>isoniazid</i></b> AUCs were approximately 67%-92% higher in the subjects who developed toxicities. ### conclusions The combined use of <b style='color:Tomato;'><i>dolutegravir</i></b> with once-weekly <b style='color:Tomato;'><i>isoniazid</i></b>-<b style='color:Tomato;'><i>rifapentine</i></b> resulted in unexpected and serious toxicities that were mediated by endogenous cytokine release. Additional investigations are necessary to examine the safety and efficacy of coadministering these medications. ### Clinical Trials Registration NCT02771249.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorA:</b>  Either 5-fluorouracil (  <span class="marker" data-anno-id="0" data-anno-label="C1">5-FU</span>  ) and  <span class="marker" data-anno-id="1" data-anno-label="C1">leucovorin</span>  for 6 months or  <span class="marker" data-anno-id="2" data-anno-label="C2">5-FU</span>  and  <span class="marker" data-anno-id="3" data-anno-label="C2">levamisole</span>  for 12 months are currently considered standard adjuvant treatment for stage III colorectal cancer . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorB:</b>  Either 5-fluorouracil (  <span class="marker" data-anno-id="0" data-anno-label="P1">5-FU</span>  ) and  <span class="marker" data-anno-id="1" data-anno-label="P1">leucovorin</span>  for 6 months or  <span class="marker" data-anno-id="2" data-anno-label="P2">5-FU</span>  and  <span class="marker" data-anno-id="3" data-anno-label="P2">levamisole</span>  for 12 months are currently considered standard adjuvant treatment for stage III colorectal cancer . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>National Cancer Institute Clinical Trials Program in Colorectal Cancer.</u></h4>Colorectal cancer will be diagnosed in approximately 150,000 patients in the USA this year. Chemotherapy has recently been shown to improve survival when given as adjuvant therapy to surgery in patients with stage III colorectal cancer. Demonstration of this benefit required large, randomized controlled trials. <b style='color:DodgerBlue;'><i>Either</i></b> <b style='color:DodgerBlue;'><i>5-fluorouracil</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>5-FU</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>leucovorin</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>6</i></b> <b style='color:DodgerBlue;'><i>months</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>5-FU</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>levamisole</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>12</i></b> <b style='color:DodgerBlue;'><i>months</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>currently</i></b> <b style='color:DodgerBlue;'><i>considered</i></b> <b style='color:DodgerBlue;'><i>standard</i></b> <b style='color:DodgerBlue;'><i>adjuvant</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>stage</i></b> <b style='color:DodgerBlue;'><i>III</i></b> <b style='color:DodgerBlue;'><i>colorectal</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b> However, current adjuvant trials are comparing continuous infusion and intravenous bolus 5-FU regimens and oral uracil/Ftorafur with intravenous 5-FU and <b style='color:Tomato;'><i>leucovorin</i></b>, as well as studying the timing of chemotherapy in the adjuvant setting. Subsequent adjuvant trials will examine newer regimens with activity in advanced colorectal cancer, as well as the efficacy of monoclonal antibodies. Other trials will study which type of surgery is optimal and whether adjuvant therapy is helpful in stage II colon cancer. Trials in metastatic disease will focus on combinations of newer agents which may improve survival in this patient group. Studies in rectal cancer will focus on determining which agents are optimal in combination with radiation therapy in the adjuvant setting. Molecular characteristics of tumor cells are being defined, which may guide therapy in the future. Careful, logically designed clinical trials will hopefully provide more efficacious therapy for this common cancer.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorA:</b>  It contains data on prophylaxis with mefloquine ( n = 48,264 ) , with chloroquine ( 6,752 ) , with  <span class="marker" data-anno-id="0" data-anno-label="C1">chloroquine</span>  plus  <span class="marker" data-anno-id="1" data-anno-label="C1">proguanil</span>  ( 19,727 ) , and with no prophylaxis ( 3,871 ) . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorB:</b>  It contains data on prophylaxis with mefloquine ( n = 48,264 ) , with chloroquine ( 6,752 ) , with chloroquine plus proguanil ( 19,727 ) , and with no prophylaxis ( 3,871 ) . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Tolerability and Effectiveness of Malaria Chemoprophylaxis with Mefloquine or Chloroquine with or without Co-medication.</u></h4>Background: To determine the relevance of drug interactions with co-medication for effectiveness and tolerability of antimalarial chemoprophylaxis. Method: A database (MALPRO2) on travelers on their flight home from Africa to Europe between July 1988 and December 1991 was reanalyzed. <b style='color:DodgerBlue;'><i>It</i></b> <b style='color:DodgerBlue;'><i>contains</i></b> <b style='color:DodgerBlue;'><i>data</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>prophylaxis</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>mefloquine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>n</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:DodgerBlue;'><i>48,264</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>chloroquine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>6,752</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>chloroquine</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>proguanil</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>19,727</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>no</i></b> <b style='color:DodgerBlue;'><i>prophylaxis</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>3,871</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The comparison of rates of malaria incidence and adverse events (AEs) between users and nonusers of co-medication was expressed by relative risk (RR). Results: Fifty-three percent of travelers (63% of females, 43% of males) used co-medication in all prophylaxis groups, with an average of 1.35 additional drugs per person and about two AEs reported per person. With the exception of antidiarrheals plus <b style='color:Tomato;'><i>mefloquine</i></b>, malaria incidence with co-medication was lower (RR = 0.8) than without co-medication. In all regimens, the proportion of travelers reporting AEs was about 1.5-fold with co-medication (p<.01); that reporting severe AEs was twice as high as compared to with no co-medication. <b style='color:Tomato;'><i>mefloquine</i></b> AE rates for various classes of co-medication were similar to that of <b style='color:Tomato;'><i>chloroquine</i></b>, with highest AE and severity rates with neuropsychiatric drugs (excluding antiepileptics, RR = 1.9 and 2.9), and lowest rates with cardiovasculars (RR = 1.1 and 1.0). Various co-medications were used with different frequencies in males and females, and the latter reported more AEs. Conclusion: These data suggest that co-medications commonly used by travelers have no significant clinical impact on safety and effectiveness of prophylaxis with <b style='color:Tomato;'><i>mefloquine</i></b> or <b style='color:Tomato;'><i>chloroquine</i></b>. Increased frequency and severity of AEs when using co-medication rather is explained by underlying illness.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorA:</b>  We randomly assigned 410 women with advanced ovarian cancer and residual masses larger than 1 cm after initial surgery to receive  <span class="marker" data-anno-id="0" data-anno-label="P1/P2">cisplatin</span>  ( 75 mg per square meter of body-surface area ) with either  <span class="marker" data-anno-id="1" data-anno-label="P1">cyclophosphamide</span>  ( 750 mg per square meter ) or  <span class="marker" data-anno-id="2" data-anno-label="P2">paclitaxel</span>  ( 135 mg per square meter over 24 hours ) . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorB:</b>  We randomly assigned 410 women with advanced ovarian cancer and residual masses larger than 1 cm after initial surgery to receive  <span class="marker" data-anno-id="0" data-anno-label="C1/P1">cisplatin</span>  ( 75 mg per square meter of body-surface area ) with either  <span class="marker" data-anno-id="1" data-anno-label="C1">cyclophosphamide</span>  ( 750 mg per square meter ) or  <span class="marker" data-anno-id="2" data-anno-label="P1">paclitaxel</span>  ( 135 mg per square meter over 24 hours ) . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.</u></h4>Chemotherapy combinations that include an alkylating agent and a platinum coordination complex have high response rates in women with advanced ovarian cancer. Such combinations provide long-term control of disease in few patients, however. We compared two combinations, <b style='color:Tomato;'><i>cisplatin</i></b> and <b style='color:Tomato;'><i>cyclophosphamide</i></b> and <b style='color:Tomato;'><i>cisplatin</i></b> and <b style='color:Tomato;'><i>paclitaxel</i></b>, in women with ovarian cancer. ### methods <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>randomly</i></b> <b style='color:DodgerBlue;'><i>assigned</i></b> <b style='color:DodgerBlue;'><i>410</i></b> <b style='color:DodgerBlue;'><i>women</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>ovarian</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>residual</i></b> <b style='color:DodgerBlue;'><i>masses</i></b> <b style='color:DodgerBlue;'><i>larger</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>cm</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>initial</i></b> <b style='color:DodgerBlue;'><i>surgery</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>receive</i></b> <b style='color:MediumOrchid;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>75</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>per</i></b> <b style='color:DodgerBlue;'><i>square</i></b> <b style='color:DodgerBlue;'><i>meter</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>body-surface</i></b> <b style='color:DodgerBlue;'><i>area</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>either</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>750</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>per</i></b> <b style='color:DodgerBlue;'><i>square</i></b> <b style='color:DodgerBlue;'><i>meter</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>135</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>per</i></b> <b style='color:DodgerBlue;'><i>square</i></b> <b style='color:DodgerBlue;'><i>meter</i></b> <b style='color:DodgerBlue;'><i>over</i></b> <b style='color:DodgerBlue;'><i>24</i></b> <b style='color:DodgerBlue;'><i>hours</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### results Three hundred eighty-six women met all the eligibility criteria. Known prognostic factors were similar in the two treatment groups. Alopecia, neutropenia, fever, and allergic reactions were reported more frequently in the <b style='color:Tomato;'><i>cisplatin</i></b>-<b style='color:Tomato;'><i>paclitaxel</i></b> group. Among 216 women with measurable disease, 73 percent in the <b style='color:Tomato;'><i>cisplatin</i></b>-<b style='color:Tomato;'><i>paclitaxel</i></b> group responded to therapy, as compared with 60 percent in the <b style='color:Tomato;'><i>cisplatin</i></b>-<b style='color:Tomato;'><i>cyclophosphamide</i></b> group (P = 0.01). The frequency of surgically verified complete response was similar in the two groups. Progression-free survival was significantly longer (P < 0.001) in the <b style='color:Tomato;'><i>cisplatin</i></b>-<b style='color:Tomato;'><i>paclitaxel</i></b> group than in the <b style='color:Tomato;'><i>cisplatin</i></b>-<b style='color:Tomato;'><i>cyclophosphamide</i></b> group (median, 18 vs. 13 months). Survival was also significantly longer (P < 0.001) in the <b style='color:Tomato;'><i>cisplatin</i></b>-<b style='color:Tomato;'><i>paclitaxel</i></b> group (median, 38 vs. 24 months). ### conclusions Incorporating <b style='color:Tomato;'><i>paclitaxel</i></b> into first-line therapy improves the duration of progression-free survival and of overall survival in women with incompletely resected stage III and stage IV ovarian cancer.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorA:</b>  All patients underwent 3 cycles of neoadjuvant  <span class="marker" data-anno-id="0" data-anno-label="P1">gemcitabine</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="P1">paclitaxel</span>  , and  <span class="marker" data-anno-id="2" data-anno-label="P1">capecitabine</span>  . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorB:</b>  All patients underwent 3 cycles of neoadjuvant  <span class="marker" data-anno-id="0" data-anno-label="C1">gemcitabine</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="C1">paclitaxel</span>  , and  <span class="marker" data-anno-id="2" data-anno-label="C1">capecitabine</span>  . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Direct percutaneous transhepatic portomesenteric venous stenting in management of locally advanced pancreatic cancer.</u></h4>Pancreatectomy with portal and/or superior mesenteric vein resection remains a controversial procedure because of high complexity and morbidity. Neoadjuvant chemotherapy has been shown to increase resectability of these locally advanced lesions. We aimed to assess the utility and efficacy of direct percutaneous transhepatic portomesenteric venous stenting (THVS) with neoadjuvant chemotherapy in increasing surgical resectability of locally advanced pancreatic carcinoma. ### methods Forty pancreatic carcinoma patients with tumor thrombus involving the portal vein and superior mesenteric vein were identified. Patients underwent THVS followed by neoadjuvant chemotherapy. Whipple procedure was offered to responders. ### results THVS was attempted in all. The tumor thrombus could not be crossed in 2 patients (95% technical success rate). <b style='color:DodgerBlue;'><i>All</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>underwent</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>cycles</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>neoadjuvant</i></b> <b style='color:MediumOrchid;'><i>gemcitabine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>capecitabine</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Disease progression was noted in 16 patients and surgery was not offered. Twenty-two patients were explored with intent-to-perform a Whipple procedure. In 7 of these (32%), extensive disease precluding surgical resection was identified and the procedure was abandoned. Whipple procedure without vascular resection was performed successfully in 15 patients (68%). There were no perioperative deaths. Negative vascular margins were noted in 3 patients and negative peripancreatic lymph nodes in 5 patients. Median survival was 17 months (range, 5 to 70 mo). In the stented nonoperative group, median survival was 9 months (range, 3 to 19 mo). The stented and resected group achieved a statistically significant (P=0.0422) survival advantage. ### conclusions THVS in combination with neoadjuvant chemotherapy can increase tumor resectability and survival in a select group of locally advanced pancreatic cancer patients.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorA:</b>  The most effective treatment regimens for advanced nonseminomatous testicular tumors employ  <span class="marker" data-anno-id="0" data-anno-label="C1">vinblastine</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="C1">CDDP</span>  and  <span class="marker" data-anno-id="2" data-anno-label="C1">bleomycin</span>  and adjunctive surgery . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorB:</b>  The most effective treatment regimens for advanced nonseminomatous testicular tumors employ  <span class="marker" data-anno-id="0" data-anno-label="P1">vinblastine</span>  , CDDP and  <span class="marker" data-anno-id="1" data-anno-label="P1">bleomycin</span>  and adjunctive surgery . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>[Preoperative chemotherapy of testicular cancer and Wilm's tumor].</u></h4>Of the various urogenital malignancies, preoperative chemotherapy is most effective for testicular cancer and Wilms' tumor. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>most</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>regimens</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>nonseminomatous</i></b> <b style='color:DodgerBlue;'><i>testicular</i></b> <b style='color:DodgerBlue;'><i>tumors</i></b> <b style='color:DodgerBlue;'><i>employ</i></b> <b style='color:MediumOrchid;'><i>vinblastine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>CDDP</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>bleomycin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>adjunctive</i></b> <b style='color:DodgerBlue;'><i>surgery</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Another effective chemotherapy regimen is combination of <b style='color:Tomato;'><i>vinblastine</i></b>, actinomycin D, <b style='color:Tomato;'><i>bleomycin</i></b>, <b style='color:Tomato;'><i>cyclophosphamide</i></b> and CDDP presented by MSKCC. Available pretreatment with 4 courses of platinum, <b style='color:Tomato;'><i>vinblastine</i></b> and <b style='color:Tomato;'><i>bleomycin</i></b> before any surgical treatment in those with massive bulk metastatic disease seems to provide the most effective cytoreduction and best survival. Donohue has shown that in a primary chemotherapy group, there is only 20% active carcinoma after primary chemotherapy, whereas in a salvage chemotherapy group there is approximately 50% active carcinoma at surgery. It must therefore be emphasized that complete remission should be obtained by primary chemotherapy and adjunctive surgery. In Wilms' tumor preoperative chemotherapy with <b style='color:Tomato;'><i>vincristine</i></b> and actinomycin D should be given.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorA:</b>  Tobramycin was probably less effective than gentamicin in combination with the penicillinase-resistant penicillins against enterococci . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorB:</b>  <span class="marker" data-anno-id="0" data-anno-label="C1">Tobramycin</span>  was probably less effective than  <span class="marker" data-anno-id="1" data-anno-label="P1">gentamicin</span>  in combination with the penicillinase-resistant  <span class="marker" data-anno-id="2" data-anno-label="C1/P1">penicillins</span>  against enterococci . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Comparative in vitro activity of nafcillin, oxacillin, and methicillin in combination with gentamicin and tobramycin against enterococci.</u></h4>The in vitro activity of <b style='color:Tomato;'><i>nafcillin</i></b>, <b style='color:Tomato;'><i>oxacillin</i></b>, and methicillin alone and in combination with <b style='color:Tomato;'><i>gentamicin</i></b> and <b style='color:Tomato;'><i>tobramycin</i></b> against 30 strains of enterococci was investigated. The penicillinase-resistant penicillins were less active than penicillin and <b style='color:Tomato;'><i>ampicillin</i></b> against the enterococci. <b style='color:Tomato;'><i>nafcillin</i></b> was more active than <b style='color:Tomato;'><i>oxacillin</i></b> and methicillin. Sixty-six percent of strains were inhibited by <b style='color:Tomato;'><i>nafcillin</i></b> at 6.25 mug/ml, but none was inhibited by <b style='color:Tomato;'><i>oxacillin</i></b> and methicillin at the same concentration. At 12.5 mug/ml, 83, 16, and 0% were inhibited by <b style='color:Tomato;'><i>nafcillin</i></b>, <b style='color:Tomato;'><i>oxacillin</i></b>, and methicillin, respectively. By using a variety of criteria and analyses, it was shown that none of the antibiotic combinations studied demonstrated enhanced killing of all strains of enterococci. <b style='color:Tomato;'><i>nafcillin</i></b>-<b style='color:Tomato;'><i>gentamicin</i></b> was the best combination, and enhanced killing was demonstrated against most strains. <b style='color:Tomato;'><i>oxacillin</i></b> was more effective than methicillin when combined with <b style='color:Tomato;'><i>gentamicin</i></b>. <b style='color:MediumOrchid;'><i>Tobramycin</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>probably</i></b> <b style='color:DodgerBlue;'><i>less</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:MediumOrchid;'><i>gentamicin</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>penicillinase-resistant</i></b> <b style='color:DodgerBlue;'><i>penicillins</i></b> <b style='color:DodgerBlue;'><i>against</i></b> <b style='color:DodgerBlue;'><i>enterococci</i></b> <b style='color:DodgerBlue;'><i>.</i></b></div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorA:</b>  We hypothesized that the brain damage mitigating effect of mild hypothermia after cardiac arrest can be enhanced with thiopental loading , and even more so with the further addition of  <span class="marker" data-anno-id="0" data-anno-label="P1">phenytoin</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">methylprednisolone</span>  . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorB:</b>  We hypothesized that the brain damage mitigating effect of mild hypothermia after cardiac arrest can be enhanced with thiopental loading , and even more so with the further addition of phenytoin and methylprednisolone . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Thiopental combination treatments for cerebral resuscitation after prolonged cardiac arrest in dogs. Exploratory outcome study.</u></h4>We postulate that mitigating the multifactorial pathogenesis of postischemic encephalopathy requires multifaceted treatments. In preparation for expensive definitive studies, we are reporting here the results of small exploratory series, compared with historic controls with the same model. <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>hypothesized</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>brain</i></b> <b style='color:DodgerBlue;'><i>damage</i></b> <b style='color:DodgerBlue;'><i>mitigating</i></b> <b style='color:DodgerBlue;'><i>effect</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>mild</i></b> <b style='color:DodgerBlue;'><i>hypothermia</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>cardiac</i></b> <b style='color:DodgerBlue;'><i>arrest</i></b> <b style='color:DodgerBlue;'><i>can</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>enhanced</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>thiopental</i></b> <b style='color:DodgerBlue;'><i>loading</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>even</i></b> <b style='color:DodgerBlue;'><i>more</i></b> <b style='color:DodgerBlue;'><i>so</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>further</i></b> <b style='color:DodgerBlue;'><i>addition</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>phenytoin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>methylprednisolone</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Twenty-four dogs (four groups of six dogs each) received VF 12.5 min no-flow, reversed with brief cardiopulmonary bypass (CPB), controlled ventilation to 20 h, and intensive care to 96 h. Group 1 with normothermia throughout and randomized group 2 with mild hypothermia (from reperfusion to 2 h) were controls. Then, group 3 received in addition, thiopental 90 mg/kg i.v. over the first 6 h. Then, group 4 received, in addition to group 2 treatment, thiopental 30 mg/kg i.v. over the first 90 min (because the larger dose had produced cardiopulmonary complications), plus <b style='color:Tomato;'><i>phenytoin</i></b> 15 mg/kg i.v. at 15 min after reperfusion, and <b style='color:Tomato;'><i>methyl<b style='color:Tomato;'><i>prednisolone</i></b></i></b> 130 mg/kg i.v. over 20 h. All dogs survived. Best overall performance categories (OPC) achieved (OPC 1 = normal, OPC 5 = brain death) were better in group 2 than group 1 (< 0.05) and numerically better in groups 3 or 4 than in groups 1 or 2. Good cerebral outcome (OPC 1 or 2) was achieved by all six dogs only in group 4 (P < 0.05 group 4 vs. 2). Best NDS were 44 +/- 3% in group 1; 20 +/- 14% in group 2 (P = 0.002); 21 +/- 15% in group 3 (NS vs. group 2); and 7 +/- 8% in group 4 (P = 0.08 vs. group 2). Total brain histologic damage scores (HDS) at 96 h were 156 +/- 38 in group 1; 81 +/- 12 in group 2 (P < 0.001 vs. group 1); 53 +/- 25 in group 3 (P = 0.02 vs. group 2); and 48 +/- 5 in group 4 (P = 0.02 vs. group 2). We conclude that after prolonged cardiac arrest, the already established brain damage mitigating effect of mild immediate postarrest hypothermia might be enhanced by thiopental, and perhaps then further enhanced by adding <b style='color:Tomato;'><i>phenytoin</i></b> and <b style='color:Tomato;'><i>methyl<b style='color:Tomato;'><i>prednisolone</i></b></i></b>.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorA:</b>  We hypothesized that Aurora A kinase ( AK ) contributes to castrate resistance in prostate cancer ( PCa ) and that inhibiting AK with  <span class="marker" data-anno-id="0" data-anno-label="C1">alisertib</span>  can resensitize PCa cells to androgen receptor ( AR ) inhibitor  <span class="marker" data-anno-id="1" data-anno-label="C1">abiraterone</span>  . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorB:</b>  We hypothesized that Aurora A kinase ( AK ) contributes to castrate resistance in prostate cancer ( PCa ) and that inhibiting AK with  <span class="marker" data-anno-id="0" data-anno-label="N1">alisertib</span>  can resensitize PCa cells to androgen receptor ( AR ) inhibitor  <span class="marker" data-anno-id="1" data-anno-label="N1">abiraterone</span>  . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>A Phase I/II Study of the Investigational Drug Alisertib in Combination With Abiraterone and Prednisone for Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Abiraterone.</u></h4>Patients with metastatic castration-resistant prostate cancer did not tolerate the combination of <b style='color:Tomato;'><i>alisertib</i></b> with <b style='color:Tomato;'><i>abiraterone</i></b> and <b style='color:Tomato;'><i>prednisone</i></b>.There was no clear signal indicating that adding <b style='color:Tomato;'><i>alisertib</i></b> might be beneficial for those patients progressing on <b style='color:Tomato;'><i>abiraterone</i></b>. ### background <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>hypothesized</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>Aurora</i></b> <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>kinase</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>AK</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>contributes</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>castrate</i></b> <b style='color:DodgerBlue;'><i>resistance</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>prostate</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>PCa</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>inhibiting</i></b> <b style='color:DodgerBlue;'><i>AK</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>alisertib</i></b> <b style='color:DodgerBlue;'><i>can</i></b> <b style='color:DodgerBlue;'><i>resensitize</i></b> <b style='color:DodgerBlue;'><i>PCa</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>androgen</i></b> <b style='color:DodgerBlue;'><i>receptor</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>AR</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>inhibitor</i></b> <b style='color:MediumOrchid;'><i>abiraterone</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods This was a phase I/II trial to determine the safety and efficacy of <b style='color:Tomato;'><i>alisertib</i></b> when given in combination with <b style='color:Tomato;'><i>abiraterone</i></b> plus <b style='color:Tomato;'><i>prednisone</i></b> (AP). Metastatic castration-resistant prostate cancer (mCRPC) patients were treated with dose escalation (<b style='color:Tomato;'><i>alisertib</i></b> at 30, 40, and 50 mg orally b.i.d., days 1-7 every 21 days) per standard 3+3 design. ### results Nine of 43 planned subjects were enrolled. The maximum tolerated dose (MTD) was not reached, and the dose-limiting toxicities (DLTs) included neutropenic fever (1 of 9), neutropenia (1 of 9), fatigue with memory impairment (1 of 9), and diarrhea/mucositis (1 of 9). No prostate-specific antigen (PSA) decrease or circulating tumor cell (CTC) changes were observed during the study. Pharmacodynamically, adding <b style='color:Tomato;'><i>alisertib</i></b> did not affect total testosterone or <b style='color:Tomato;'><i>dehydroepiandrosterone</i></b> (DHEA) levels. There was some change in neuroendocrine markers after therapy. Mean duration on study was 2.5 months. The trial was terminated early. ### conclusion A tolerable dose of <b style='color:Tomato;'><i>alisertib</i></b> in combination with AP in mCRPC was not established in this study. There was no clear signal indicating that <b style='color:Tomato;'><i>alisertib</i></b> might be beneficial for patients with mCRPC progressing on <b style='color:Tomato;'><i>abiraterone</i></b>.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorA:</b>  The aim of the present investigation was to study and characterize the effect of  <span class="marker" data-anno-id="0" data-anno-label="C1">voriconazole</span>  on the fungicidal activity of  <span class="marker" data-anno-id="1" data-anno-label="C1">amphotericin B.</span> </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorB:</b>  The aim of the present investigation was to study and characterize the effect of voriconazole on the fungicidal activity of amphotericin B. </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Characterization of the inhibitory effect of voriconazole on the fungicidal activity of amphotericin B against Candida albicans in an in vitro kinetic model.</u></h4> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>aim</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>present</i></b> <b style='color:DodgerBlue;'><i>investigation</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>characterize</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>effect</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>voriconazole</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>fungicidal</i></b> <b style='color:DodgerBlue;'><i>activity</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>amphotericin</i></b> <b style='color:DodgerBlue;'><i>B.</i></b> ### methods Four strains of Candida albicans susceptible to <b style='color:Tomato;'><i>voriconazole</i></b> were exposed to <b style='color:Tomato;'><i>voriconazole</i></b> and <b style='color:Tomato;'><i>amphotericin</i></b> B, either alone, simultaneously or sequentially in an in vitro kinetic model. Bolus doses resulting in <b style='color:Tomato;'><i>voriconazole</i></b> and <b style='color:Tomato;'><i>amphotericin</i></b> B concentrations of 0.005-5 and 2.5 mg/L, respectively, were administered. Antifungal-containing RPMI 1640 was eliminated and replaced by a fresh medium using a peristaltic pump, with a flow rate adjusted to obtain the desired half-lives. With two drugs tested, a computer-controlled dosing pump compensated for differences in the elimination rates. Using static time-kill methodology, one C. albicans strain was exposed to 5 mg/L <b style='color:Tomato;'><i>voriconazole</i></b> for varying durations followed by 2.5 mg/L <b style='color:Tomato;'><i>amphotericin</i></b> B after three repeated washes of <b style='color:Tomato;'><i>voriconazole</i></b>. ### results <b style='color:Tomato;'><i>voriconazole</i></b> and <b style='color:Tomato;'><i>amphotericin</i></b> B treatment alone resulted in fungistatic and fungicidal activities, respectively. Simultaneous administration of <b style='color:Tomato;'><i>voriconazole</i></b> and <b style='color:Tomato;'><i>amphotericin</i></b> B resulted in fungicidal activity, whereas only fungistatic activity was observed when repeated doses of <b style='color:Tomato;'><i>amphotericin</i></b> B were administered sequentially after <b style='color:Tomato;'><i>voriconazole</i></b> at 24-96 h. The inhibition of the fungicidal activity of <b style='color:Tomato;'><i>amphotericin</i></b> B was <b style='color:Tomato;'><i>voriconazole</i></b> dose-dependent, but seemed to be recovered once the <b style='color:Tomato;'><i>voriconazole</i></b> concentration fell below the MIC. The fungicidal activity was quickly regained after the removal of <b style='color:Tomato;'><i>voriconazole</i></b>, irrespective of the duration of <b style='color:Tomato;'><i>voriconazole</i></b> pre-exposure. ### conclusions <b style='color:Tomato;'><i>voriconazole</i></b> inhibited the fungicidal effect of sequentially administered <b style='color:Tomato;'><i>amphotericin</i></b> B in a concentration- and time-dependent manner; the clinical significance of this needs further investigation.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorA:</b>  Combinations of  <span class="marker" data-anno-id="0" data-anno-label="P1">penicillin</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">streptomycin</span>  and  <span class="marker" data-anno-id="2" data-anno-label="P2">penicillin</span>  and  <span class="marker" data-anno-id="3" data-anno-label="P2">amikacin</span>  were synergistic only against those strains that were not highly resistant to streptomycin and kanamycin , respectively . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorB:</b>  Combinations of  <span class="marker" data-anno-id="0" data-anno-label="C1">penicillin</span>  and  <span class="marker" data-anno-id="1" data-anno-label="C1">streptomycin</span>  and  <span class="marker" data-anno-id="2" data-anno-label="C2">penicillin</span>  and  <span class="marker" data-anno-id="3" data-anno-label="C2">amikacin</span>  were synergistic only against those strains that were not highly resistant to streptomycin and kanamycin , respectively . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Species-specific resistance to antimocrobial synergism in Streptococcus faecium and Streptococcus faecalis.</u></h4>Combinations of penicillin with various aminoglycosidic aminocyclitols were tested against a collection of clinical isolates of Streptococcus faecium in vitro and were used to treat endocarditis caused by S. faecium in the rabbit model. S. faecium proved more resistant to penicillin than Streptococcus faecalis. Even more striking, however, was the resistance to in vitro synergism by combinations of penicillin and various aminoglycosides. At clinically achievable concentrations, penicillin-<b style='color:Tomato;'><i>gentamicin</i></b> was the only combination that was synergistic against all strains that were tested. <b style='color:DodgerBlue;'><i>Combinations</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>penicillin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>streptomycin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>penicillin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>amikacin</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>synergistic</i></b> <b style='color:DodgerBlue;'><i>only</i></b> <b style='color:DodgerBlue;'><i>against</i></b> <b style='color:DodgerBlue;'><i>those</i></b> <b style='color:DodgerBlue;'><i>strains</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>not</i></b> <b style='color:DodgerBlue;'><i>highly</i></b> <b style='color:DodgerBlue;'><i>resistant</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>streptomycin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>kanamycin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>respectively</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Combinations of penicillin with <b style='color:Tomato;'><i>kanamycin</i></b>, <b style='color:Tomato;'><i>tobramycin</i></b>, <b style='color:Tomato;'><i>sisomicin</i></b>, or <b style='color:Tomato;'><i>netilmicin</i></b> failed to produce synergism against any of these strains. The possible clinical significance of these findings was verified by use of the rabbit model of endocarditis. Combinations of penicillin with <b style='color:Tomato;'><i>gentamicin</i></b> or <b style='color:Tomato;'><i>streptomycin</i></b> were synergistic in the therapy of endocarditis that was produced by a strain of S. faecium that did not have a high level of resistance to aminoglycosides. However, the combination of penicillin and <b style='color:Tomato;'><i>netilmicin</i></b> was no more effective than penicillin alone.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorA:</b>  compared to  <span class="marker" data-anno-id="0" data-anno-label="N2">busulfan</span>  and  <span class="marker" data-anno-id="1" data-anno-label="N2">cyclophosphamide</span>  as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorB:</b>  compared to  <span class="marker" data-anno-id="0" data-anno-label="P1">busulfan</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">cyclophosphamide</span>  as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u><b style='color:DodgerBlue;'><i>compared</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>busulfan</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>conditioning</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>allogeneic</i></b> <b style='color:DodgerBlue;'><i>stem</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>transplant</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>matched</i></b> <b style='color:DodgerBlue;'><i>siblings</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>unrelated</i></b> <b style='color:DodgerBlue;'><i>donors</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>acute</i></b> <b style='color:DodgerBlue;'><i>myeloid</i></b> <b style='color:DodgerBlue;'><i>leukemia</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h4><b style='color:Tomato;'><i>busulfan</i></b> plus <b style='color:Tomato;'><i>cyclophosphamide</i></b> (BuCy) is the traditional conditioning regimen for allogeneic stem cell transplant (allo-SCT) for young, fit patients with acute myeloid leukemia (AML). The <b style='color:Tomato;'><i>thiotepa</i></b>-<b style='color:Tomato;'><i>busulfan</i></b>-<b style='color:Tomato;'><i>fludarabine</i></b> (TBF) protocol has recently demonstrated promising outcome in cord blood and haploidentical SCT; however, there is limited evidence about this regimen in transplant from matched siblings (MSD) and unrelated donors (UD). We retrospectively compared outcomes of 2523 patients aged 18-50 with AML in remission, undergoing transplant from MSD or UD prepared with either TBF or BuCy conditioning. A 1:3 pair-matched analysis was performed: 146 patients receiving TBF were compared with 438 patients receiving BuCy. Relapse risk was significantly lower in the TBF when compared with BuCy group (HR 0.6, P = .02), while NRM did not differ. No significant difference was observed in LFS and OS between the two regimens. TBF was associated with a trend towards higher risk of grades III-IV aGVHD (HR 1.8, P = .06) and inferior cGVHD (HR 0.7, P = .04) when compared with BuCy. In patients undergoing transplant in first remission, the advantage for TBF in terms of relapse was more evident (HR 0.4, P = .02), leading to a trend for better LFS in favor of TBF (HR 0.7, P = .10), while OS did not differ between the two cohorts. In conclusion, TBF represents a valid myeloablative conditioning regimen providing significantly lower relapse and similar survival when compared with BuCy. Patients in first remission appear to gain the most from this protocol, as in this subgroup a tendency for better LFS was observed when compared with BuCy.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorA:</b>  Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen : a TransATAC study . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorB:</b>  Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with  <span class="marker" data-anno-id="0" data-anno-label="C1">anastrozole</span>  or  <span class="marker" data-anno-id="1" data-anno-label="C1">tamoxifen</span>  : a TransATAC study . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u><b style='color:DodgerBlue;'><i>Prediction</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>risk</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>distant</i></b> <b style='color:DodgerBlue;'><i>recurrence</i></b> <b style='color:DodgerBlue;'><i>using</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>21-gene</i></b> <b style='color:DodgerBlue;'><i>recurrence</i></b> <b style='color:DodgerBlue;'><i>score</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>node-negative</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>node-positive</i></b> <b style='color:DodgerBlue;'><i>postmenopausal</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>anastrozole</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>tamoxifen</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>TransATAC</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h4>PURPOSE To determine whether the Recurrence Score (RS) provided independent information on risk of distant recurrence (DR) in the <b style='color:Tomato;'><i>tamoxifen</i></b> and <b style='color:Tomato;'><i>anastrozole</i></b> arms of the Arimidex, <b style='color:Tomato;'><i>tamoxifen</i></b>, Alone or in Combination (ATAC) Trial. PATIENTS AND METHODS RNA was extracted from 1,372 tumor blocks from postmenopausal patients with hormone receptor-positive primary breast cancer in the monotherapy arms of ATAC. Twenty-one genes were assessed by quantitative reverse transcriptase polymerase chain reaction, and the RS was calculated. Cox proportional hazards models assessed the value of adding RS to a model with clinical variables (age, tumor size, grade, and treatment) in node-negative (N0) and node-positive (N+) women. RESULTS Reportable scores were available from 1,231 evaluable patients (N0, n = 872; N+, n = 306; and node status unknown, n = 53); 72, 74, and six DRs occurred in N0, N+, and node status unknown patients, respectively. For both N0 and N+ patients, RS was significantly associated with time to DR in multivariate analyses (P < .001 for N0 and P = .002 for N+). RS also showed significant prognostic value beyond that provided by Adjuvant! Online (P < .001). Nine-year DR rates in low (RS < 18), intermediate (RS = 18 to 30), and high RS (RS > or = 31) groups were 4%, 12%, and 25%, respectively, in N0 patients and 17%, 28%, and 49%, respectively, in N+ patients. The prognostic value of RS was similar in <b style='color:Tomato;'><i>anastrozole</i></b>- and <b style='color:Tomato;'><i>tamoxifen</i></b>-treated patients. CONCLUSION This study confirmed the performance of RS in postmenopausal HR+ patients treated with <b style='color:Tomato;'><i>tamoxifen</i></b> in a large contemporary population and demonstrated that RS is an independent predictor of DR in N0 and N+ hormone receptor-positive patients treated with <b style='color:Tomato;'><i>anastrozole</i></b>, adding value to estimates with standard clinicopathologic features.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorA:</b>  The molecular subtypes of breast cancer can predict responses to the combinational treatment of  <span class="marker" data-anno-id="0" data-anno-label="C1">doxorubicin</span>  with  <span class="marker" data-anno-id="1" data-anno-label="C1">docetaxel</span>  , and ERBB2 </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorB:</b>  The molecular subtypes of breast cancer can predict responses to the combinational treatment of  <span class="marker" data-anno-id="0" data-anno-label="P1">doxorubicin</span>  with  <span class="marker" data-anno-id="1" data-anno-label="P1">docetaxel</span>  , and ERBB2 </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Combinational Treatment of Doxorubicin With Neoadjuvant Docetaxel for Different Subtypes of Patients With Breast Cancer.</u></h4>The aim of this study is to characterize the effect of chemotherapy drug <b style='color:Tomato;'><i>doxorubicin</i></b> with neoadjuvant drug <b style='color:Tomato;'><i>docetaxel</i></b> for different molecular subtypes. ### methods A total of 83 patients with late-stage breast cancer were chosen to undergo treatment and compared to these patients to the combinational treatment to identify the molecular characteristics that can predict the responses. ### results Total response rate is 81.9% (68/83 patients). Among them, 7 patients show pathological complete response of 8.4%, 12 patients show clinical complete response of 14.5%, 49 patients show partial response of 59%, and 15 patients show stable disease of 18.1%. The comparison among different subtypes of breast cancer, including luminal A, luminal B, basal-like, and ERBB2 ### conclusion <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>molecular</i></b> <b style='color:DodgerBlue;'><i>subtypes</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>can</i></b> <b style='color:DodgerBlue;'><i>predict</i></b> <b style='color:DodgerBlue;'><i>responses</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combinational</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>ERBB2</i></b></div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorA:</b>  All consecutive patients with advanced BTC received the GEMOX regimen in a setting outside a study :  <span class="marker" data-anno-id="0" data-anno-label="P1">gemcitabine</span>  1,000 mg/m(2 ) on day 1 , and  <span class="marker" data-anno-id="1" data-anno-label="P1">oxaliplatin</span>  100 mg/m(2 ) on day 2 , treatment repeated every 2 weeks until progression or unacceptable toxicity . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorB:</b>  All consecutive patients with advanced BTC received the GEMOX regimen in a setting outside a study : gemcitabine 1,000 mg/m(2 ) on day 1 , and oxaliplatin 100 mg/m(2 ) on day 2 , treatment repeated every 2 weeks until progression or unacceptable toxicity . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Experience of gemcitabine plus oxaliplatin chemotherapy in patients with advanced biliary tract carcinoma.</u></h4>The combination <b style='color:Tomato;'><i>gemcitabine</i></b>-<b style='color:Tomato;'><i>oxaliplatin</i></b> (GEMOX) is frequently used in patients with advanced biliary tract carcinoma (BTC). However, this is only based on phase II studies performed in selected patients.We assessed the efficacy and safety of the GEMOX regimen in non-selected patients with advanced BTC. ### methods <b style='color:DodgerBlue;'><i>All</i></b> <b style='color:DodgerBlue;'><i>consecutive</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>BTC</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>GEMOX</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>setting</i></b> <b style='color:DodgerBlue;'><i>outside</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:MediumOrchid;'><i>gemcitabine</i></b> <b style='color:DodgerBlue;'><i>1,000</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>oxaliplatin</i></b> <b style='color:DodgerBlue;'><i>100</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>repeated</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>until</i></b> <b style='color:DodgerBlue;'><i>progression</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>unacceptable</i></b> <b style='color:DodgerBlue;'><i>toxicity</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### results Forty-four patients were enrolled. ### efficacy 1 complete and 6 partial responses (objective response rate = 16.3%), 18 tumour stabilizations (41.9%, disease control rate = 58.1%), median progression-free survival was 5.0 months and median overall survival was 11.0 months. ### toxicity grade 3 neuropathy in 4 patients, grade 3 asthenia in 5 patients. ### conclusion The GEMOX combination was well tolerated, with a modest activity in non-selected patients with advanced BTC. This regimen should be compared to the new standard <b style='color:Tomato;'><i>gemcitabine</i></b>-<b style='color:Tomato;'><i>cisplatin</i></b> combination.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorA:</b>  Evaluation of  <span class="marker" data-anno-id="0" data-anno-label="C1">tamoxifen</span>  plus  <span class="marker" data-anno-id="1" data-anno-label="C1">letrozole</span>  with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorB:</b>  Evaluation of  <span class="marker" data-anno-id="0" data-anno-label="P1">tamoxifen</span>  plus  <span class="marker" data-anno-id="1" data-anno-label="P1">letrozole</span>  with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u><b style='color:DodgerBlue;'><i>Evaluation</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>tamoxifen</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>letrozole</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>assessment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>pharmacokinetic</i></b> <b style='color:DodgerBlue;'><i>interaction</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>postmenopausal</i></b> <b style='color:DodgerBlue;'><i>women</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h4>The goals of this clinical trial involving postmenopausal women with metastatic breast cancer were to: (a) examine the effects of <b style='color:Tomato;'><i>letrozole</i></b> on <b style='color:Tomato;'><i>tamoxifen</i></b> (TAM) pharmacokinetics; (b) examine estrogen suppression in patients receiving TAM plus <b style='color:Tomato;'><i>letrozole</i></b>; and (c) evaluate tolerability, toxicity, objective response, and time to progression for the combination. Postmenopausal women with measurable or evaluable metastatic breast cancer received TAM (20 mg daily) for 6 weeks, and then <b style='color:Tomato;'><i>letrozole</i></b> (2.5 mg daily) was added. To examine for any effect of <b style='color:Tomato;'><i>letrozole</i></b> on the levels of TAM and two metabolites [N-desmethyl-TAM and 4-hydroxy-TAM], serum samples were obtained at 6, 12, 18, and 24 weeks. To examine for aromatase inhibition, serum samples were obtained before treatment and at 6, 12, 18, and 24 weeks for estradiol, <b style='color:Tomato;'><i>estrone</i></b> (E1) E1 sulfate, and sex hormone-binding globulin. A total of 34 patients were entered on this trial, and 23 patients were still on study at week 24, 18 of whom had blood samples available at both week 6 and week 24. The 95% confidence interval for the mean difference between levels at week 24 and levels at week 6 was -34 to 15 ng/ml for TAM, -35 to 45 ng/ml for N-desmethyl-TAM, and -1 to 2 for 4-hydroxy-TAM. For estradiol, a significant decrease (median, 88.5%; range, 73.7-95.2%) was identified after 6 weeks of <b style='color:Tomato;'><i>letrozole</i></b>, which was maintained for an additional 12 weeks. Similar significant reductions were identified for E1. E1 sulfate levels increased after 6 weeks of TAM alone but then decreased significantly after the addition of <b style='color:Tomato;'><i>letrozole</i></b>. Sex hormone-binding globulin levels were significantly elevated after 6 weeks of TAM alone and remained elevated after the addition of <b style='color:Tomato;'><i>letrozole</i></b>. Six of the 34 patients (17.6%) achieved an objective response (95% confidence interval, 6.8-34.5%), with a median time to disease progression of 7.6 months. There was no indication of a systematic decrease in TAM, N-desmethyl-TAM, or 4-hydroxy-TAM after the additional of <b style='color:Tomato;'><i>letrozole</i></b>. Estrogen suppression induced by <b style='color:Tomato;'><i>letrozole</i></b> was substantial despite the concomitant administration of TAM. The antitumor effect of TAM plus <b style='color:Tomato;'><i>letrozole</i></b> was less than expected.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorA:</b>  Posttransplant immunosuppression to prevent graft-versus-host disease ( GVHD ) consisted of  <span class="marker" data-anno-id="0" data-anno-label="C1">cyclosporine</span>  and  <span class="marker" data-anno-id="1" data-anno-label="C1">prednisone</span>  ( CSA/PSE ) . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorB:</b>  Posttransplant immunosuppression to prevent graft-versus-host disease ( GVHD ) consisted of  <span class="marker" data-anno-id="0" data-anno-label="P1">cyclosporine</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">prednisone</span>  ( CSA/PSE ) . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>A prospective randomized comparison of total body irradiation-etoposide versus busulfan-cyclophosphamide as preparatory regimens for bone marrow transplantation in patients with leukemia who were not in first remission: a Southwest Oncology Group study.</u></h4>Two novel preparatory regimens for conditioning of patients with leukemia for allogeneic bone marrow transplantation (BMT) from histocompatible sibling donors have been tested in a phase III trial under the auspices of the Southwest Oncology Group (SWOG 8612). These two regimens consisted either of fractionated total body irradiation and <b style='color:Tomato;'><i>etoposide</i></b> (FTBI/VP-16) or high-dose <b style='color:Tomato;'><i>busulfan</i></b> with <b style='color:Tomato;'><i>cyclophosphamide</i></b> (BU/CY). Only patients who had failed prior conventional management at least once were study eligible, ie, no patients with acute leukemia in first remission (CR) or in first chronic phase (CP) of chronic myelogenous leukemia (CML) participated. Patients were stratified according to the following risk criteria: "good-risk" patients were those who were in second CR of their acute leukemia or in accelerated phase (AP) of CML; "poor-risk" patients had further advanced stages of leukemia. During a 52-month period, 131 patients were registered of whom 122 (93%) were study eligible. Sixty-one eligible patients were randomized to the FTBI/VP-16 arm and 61 to the BU/CY regimen. Of these 122 patients, 114 (93%) proceeded to BMT according to protocol. <b style='color:DodgerBlue;'><i>Posttransplant</i></b> <b style='color:DodgerBlue;'><i>immunosuppression</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>prevent</i></b> <b style='color:DodgerBlue;'><i>graft-versus-host</i></b> <b style='color:DodgerBlue;'><i>disease</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>GVHD</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>consisted</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>cyclosporine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>prednisone</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>CSA/PSE</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Neither overall survival nor disease-free survival (DFS) differed significantly between the two treatment groups (P = .89 and .69, respectively). Estimated DFS for "good-risk" patients who had been prepared with the FTBI/VP-16 regimen was 55% +/- 11%, as compared with patients treated with BU/CY whose DFS figure was 34% +/- 10% (P = .30). For "poor-risk" candidates, the DFS rates at 24 months were 17% +/- 6% (for FTBI/VP-16) and 24% +/- 8% (for BU/CY), respectively (P = .81). These figures do not differ significantly, especially in view of the fact that the "good-risk" patients prepared with the FTBI/VP-16 regimen were younger than those treated with BU/CY. Both regimens were well tolerated with no regimen-related deaths encountered during the 6-week period after BMT. This study also confirmed the efficacy of the CSA/PSE combination in the prevention of GVHD with 23 of 113 (20%) of BMT recipients developing moderate to severe acute GVHD. The leading cause for treatment failure was leukemic relapse (45 of the 114 BMT recipients suffered a recurrence of their leukemia), whereas 38 patients died without evidence of relapse. Thirty-one patients are alive and in continued CR after marrow transplantation; four are alive in relapse.(ABSTRACT TRUNCATED AT 400 WORDS)</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorA:</b>  Recent randomized controlled trials ( RCT ) have failed to demonstrate the efficacy of widely used therapies , such as  <span class="marker" data-anno-id="0" data-anno-label="N1">rituximab</span>  plus intravenous immunoglobulin or proteasome inhibition (  <span class="marker" data-anno-id="1" data-anno-label="N1">bortezomib</span>  ) , reinforcing a great need for new therapeutic concepts . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorB:</b>  Recent randomized controlled trials ( RCT ) have failed to demonstrate the efficacy of widely used therapies , such as  <span class="marker" data-anno-id="0" data-anno-label="N1/N2">rituximab</span>  plus  <span class="marker" data-anno-id="1" data-anno-label="N1">intravenous immunoglobulin</span>  or proteasome inhibition (  <span class="marker" data-anno-id="2" data-anno-label="N2">bortezomib</span>  ) , reinforcing a great need for new therapeutic concepts . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trial.</u></h4>Late antibody-mediated rejection (ABMR) triggered by donor-specific antibodies (DSA) is a cardinal cause of kidney allograft dysfunction and loss. Diagnostic criteria for this rejection type are well established, but effective treatment remains a major challenge. <b style='color:DodgerBlue;'><i>Recent</i></b> <b style='color:DodgerBlue;'><i>randomized</i></b> <b style='color:DodgerBlue;'><i>controlled</i></b> <b style='color:DodgerBlue;'><i>trials</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>RCT</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>failed</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>demonstrate</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>widely</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>therapies</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>such</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:MediumOrchid;'><i>rituximab</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:DodgerBlue;'><i>intravenous</i></b> <b style='color:DodgerBlue;'><i>immunoglobulin</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>proteasome</i></b> <b style='color:DodgerBlue;'><i>inhibition</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>bortezomib</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>reinforcing</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>great</i></b> <b style='color:DodgerBlue;'><i>need</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>new</i></b> <b style='color:DodgerBlue;'><i>therapeutic</i></b> <b style='color:DodgerBlue;'><i>concepts</i></b> <b style='color:DodgerBlue;'><i>.</i></b> One promising target in this context may be interleukin-6 (IL-6), a pleiotropic cytokine known to play an important role in inflammation and adaptive immunity. ### methods This investigator-driven RCT was designed to assess the safety and efficacy of <b style='color:Tomato;'><i>clazakizumab</i></b>, a genetically engineered humanized monoclonal antibody directed against IL-6. The study will include 20 DSA-positive kidney allograft recipients diagnosed with ABMR ≥ 365 days after transplantation. Participants will be recruited at two study sites in Austria and Germany (Medical University of Vienna; Charité University Medicine Berlin). First, patients will enter a three-month double-blind RCT (1,1 randomization, stratification according to ABMR phenotype and study site) and will receive either <b style='color:Tomato;'><i>clazakizumab</i></b> (subcutaneous administration of 25 mg in monthly intervals) or placebo. In a second open-label part of the trial (months 4-12), all patients will receive <b style='color:Tomato;'><i>clazakizumab</i></b> at 25 mg every month. The primary endpoint is safety and tolerability. Secondary endpoints are the pharmacokinetics and pharmacodynamics of <b style='color:Tomato;'><i>clazakizumab</i></b>, its effect on drug metabolism in the liver, DSA characteristics, morphological ABMR lesions and molecular gene expression patterns in three- and 12-month protocol biopsies, serum/urinary biomarkers of inflammation and endothelial activation/injury, Torque Teno viral load as a measure of overall immunosuppression, kidney function, urinary protein excretion, as well as transplant and patient survival. ### discussion Currently, there is no treatment proven to be effective in halting the progression of late ABMR. Based on the hypothesis that antagonizing the effects of IL-6 improves the outcome of DSA-positive late ABMR by counteracting DSA-triggered inflammation and B cell/plasma cell-driven alloimmunity, we suggest that our trial has the potential to provide proof of concept of a novel treatment of this type of rejection. ### Trial Registration ClinicalTrials.gov, NCT03444103 . Registered on 23 February 2018 (retrospective registration).</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorA:</b>  Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorB:</b>  Clinical activity of  <span class="marker" data-anno-id="0" data-anno-label="P1">enzalutamide</span>  versus  <span class="marker" data-anno-id="1" data-anno-label="P2">docetaxel</span>  in men with castration-resistant prostate cancer progressing after  <span class="marker" data-anno-id="2" data-anno-label="P1/P2">abiraterone</span>  . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u><b style='color:DodgerBlue;'><i>Clinical</i></b> <b style='color:DodgerBlue;'><i>activity</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>enzalutamide</i></b> <b style='color:DodgerBlue;'><i>versus</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>men</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>castration-resistant</i></b> <b style='color:DodgerBlue;'><i>prostate</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>progressing</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:MediumOrchid;'><i>abiraterone</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h4>The optimal sequencing of the multiple active agents now available for metastatic castration-resistant prostate cancer (mCRPC) is unclear. Prior reports have suggested diminished responses to sequential lines of androgen receptor (AR)-targeted therapies, but it is unknown whether subsequent taxane-based chemotherapy may be more effective than sequential AR-targeting treatment. We sought to evaluate the clinical activity of <b style='color:Tomato;'><i>enzalutamide</i></b> versus <b style='color:Tomato;'><i>docetaxel</i></b> in men with mCRPC who progressed on <b style='color:Tomato;'><i>abiraterone</i></b>. ### methods We performed a single-institution retrospective analysis of consecutive mCRPC patients who had progressed on <b style='color:Tomato;'><i>abiraterone</i></b> therapy and subsequently received either <b style='color:Tomato;'><i>enzalutamide</i></b> (n=30) or <b style='color:Tomato;'><i>docetaxel</i></b> (n=31). We evaluated clinical outcomes including prostate-specific antigen decline of >30% (PSA30) or >50% (PSA50), PSA-progression-free survival (PSA-PFS), and clinical/radiographic PFS. We performed multivariable modeling to control for baseline and on-treatment differences between groups. ### results Compared to subjects who received <b style='color:Tomato;'><i>enzalutamide</i></b> post-<b style='color:Tomato;'><i>abiraterone</i></b>, subjects who received <b style='color:Tomato;'><i>docetaxel</i></b> post-<b style='color:Tomato;'><i>abiraterone</i></b> had more bone metastases, more visceral metastases, higher baseline PSA, and had more frequent PSA tests while on-treatment. There were no significant differences in PSA30 (41% for <b style='color:Tomato;'><i>enzalutamide</i></b> vs. 53% for <b style='color:Tomato;'><i>docetaxel</i></b>) or PSA50 (34% vs. 40%) response rates between the two groups; there remained no difference after stratifying by presence/absence of prior response to <b style='color:Tomato;'><i>abiraterone</i></b>. Median PSA-PFS was 4.1 versus 4.1 months for the <b style='color:Tomato;'><i>enzalutamide</i></b> and <b style='color:Tomato;'><i>docetaxel</i></b> cohorts, respectively (HR 1.35, 95% CI, 0.53-3.66, P=0.502). Median PFS was 4.7 versus 4.4 months, respectively (HR 1.44, 95% CI, 0.77-2.71, P=0.257). PSA-PFS and PFS did not differ after stratifying by prior response to <b style='color:Tomato;'><i>abiraterone</i></b>. In multivariable analyses, there were no significant differences in PSA-PFS or PFS between the two groups. ### conclusions Treatment with either <b style='color:Tomato;'><i>enzalutamide</i></b> or <b style='color:Tomato;'><i>docetaxel</i></b> produced modest PSA responses and PFS intervals in this <b style='color:Tomato;'><i>abiraterone</i></b>-pretreated mCRPC population. In this retrospective study with small sample size, no significant differences in outcomes were observed between groups. Therefore, either <b style='color:Tomato;'><i>enzalutamide</i></b> or <b style='color:Tomato;'><i>docetaxel</i></b> may be a reasonable option in men who have progressed on <b style='color:Tomato;'><i>abiraterone</i></b>.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorA:</b>  The experimental protocol was as follows : ( 1 ) at time zero , intravenous infusion of  <span class="marker" data-anno-id="0" data-anno-label="P1/C1">ritodrine</span>  was begun ; ( 2 ) at 120 min , 2 %  <span class="marker" data-anno-id="1" data-anno-label="P1/C1">lidocaine</span>  was given epidurally to achieve a sensory level of at least T6 ; and ( 3 ) at 135 min , an intravenous bolus of either  <span class="marker" data-anno-id="2" data-anno-label="P1">ephedrine</span>  ,  <span class="marker" data-anno-id="3" data-anno-label="C1">phenylephrine</span>  , or normal saline-control was given , followed by a continuous intravenous infusion of the same agent for 30 min . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorB:</b>  The experimental protocol was as follows : ( 1 ) at time zero , intravenous infusion of  <span class="marker" data-anno-id="0" data-anno-label="P1/P2">ritodrine</span>  was begun ; ( 2 ) at 120 min , 2 %  <span class="marker" data-anno-id="1" data-anno-label="P1/P2">lidocaine</span>  was given epidurally to achieve a sensory level of at least T6 ; and ( 3 ) at 135 min , an intravenous bolus of either  <span class="marker" data-anno-id="2" data-anno-label="P1">ephedrine</span>  ,  <span class="marker" data-anno-id="3" data-anno-label="P2">phenylephrine</span>  , or normal saline-control was given , followed by a continuous intravenous infusion of the same agent for 30 min . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Ephedrine remains the vasopressor of choice for treatment of hypotension during ritodrine infusion and epidural anesthesia.</u></h4>Historically, ephedrine has been the vasopressor of choice for treatment of most cases of hypotension in obstetric patients. However, the choice of vasopressor in the parturient receiving a beta-adrenergic agent for tocolysis has not been evaluated extensively. The current study evaluated whether ephedrine or <b style='color:Tomato;'><i>phenylephrine</i></b> better restores uterine blood flow and fetal oxygenation during <b style='color:Tomato;'><i>ritodrine</i></b> infusion and epidural anesthesia-induced hypotension in gravid ewes. ### methods Fourteen chronically instrumented gravid ewes between 0.8 and 0.9 timed gestational age were used. On separate days, each animal underwent the experimental protocol with one of three agents: ephedrine, <b style='color:Tomato;'><i>phenylephrine</i></b>, and normal saline-control. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>experimental</i></b> <b style='color:DodgerBlue;'><i>protocol</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>follows</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>time</i></b> <b style='color:DodgerBlue;'><i>zero</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>intravenous</i></b> <b style='color:DodgerBlue;'><i>infusion</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>ritodrine</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>begun</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>120</i></b> <b style='color:DodgerBlue;'><i>min</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:MediumOrchid;'><i>lidocaine</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>given</i></b> <b style='color:DodgerBlue;'><i>epidurally</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>achieve</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>sensory</i></b> <b style='color:DodgerBlue;'><i>level</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>least</i></b> <b style='color:DodgerBlue;'><i>T6</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>135</i></b> <b style='color:DodgerBlue;'><i>min</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>intravenous</i></b> <b style='color:DodgerBlue;'><i>bolus</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>either</i></b> <b style='color:DodgerBlue;'><i>ephedrine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>phenylephrine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>normal</i></b> <b style='color:DodgerBlue;'><i>saline-control</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>given</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>continuous</i></b> <b style='color:DodgerBlue;'><i>intravenous</i></b> <b style='color:DodgerBlue;'><i>infusion</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>same</i></b> <b style='color:DodgerBlue;'><i>agent</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>30</i></b> <b style='color:DodgerBlue;'><i>min</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In the ephedrine and <b style='color:Tomato;'><i>phenylephrine</i></b> experiments, the rate of infusion was adjusted to maintain maternal mean arterial pressure close to baseline. ### results <b style='color:Tomato;'><i>ritodrine</i></b> infusion alone significantly increased maternal heart rate and cardiac output in all three groups. Epidural anesthesia during <b style='color:Tomato;'><i>ritodrine</i></b> infusion significantly decreased maternal mean arterial pressure, heart rate, cardiac output, uterine blood flow, and fetal arterial oxygen tension for each of the three groups. Both ephedrine and <b style='color:Tomato;'><i>phenylephrine</i></b> restored maternal mean arterial pressure to baseline, as designed. Ephedrine significantly increased uterine blood flow and fetal arterial oxygen tension when compared with normal saline--control, but <b style='color:Tomato;'><i>phenylephrine</i></b> did not. <b style='color:Tomato;'><i>phenylephrine</i></b> significantly increased uterine vascular resistance when compared with normal saline--control, but ephedrine did not. ### conclusions Although ephedrine and <b style='color:Tomato;'><i>phenylephrine</i></b> provided similar restoration of maternal mean arterial pressure, ephedrine was superior to <b style='color:Tomato;'><i>phenylephrine</i></b> in restoring uterine blood flow during <b style='color:Tomato;'><i>ritodrine</i></b> infusion and epidural anesthesia-induced hypotension in gravid ewes. Also, ephedrine, but not <b style='color:Tomato;'><i>phenylephrine</i></b>, significantly improved fetal oxygenation, when compared to normal saline--control.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorA:</b>  This study aims to compare the biological , molecular , pharmacological , and clinical characteristics of these three treatment modalities for SARS-COV-2 infections , Chloroquine and Hydroxychloroquine , Convalescent Plasma , and Remdesivir . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorB:</b>  This study aims to compare the biological , molecular , pharmacological , and clinical characteristics of these three treatment modalities for SARS-COV-2 infections ,  <span class="marker" data-anno-id="0" data-anno-label="C1">Chloroquine</span>  and  <span class="marker" data-anno-id="1" data-anno-label="C1">Hydroxychloroquine</span>  , Convalescent Plasma , and Remdesivir . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Biological, molecular and pharmacological characteristics of chloroquine, hydroxychloroquine, convalescent plasma, and remdesivir for COVID-19 pandemic: A comparative analysis.</u></h4>The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, also known as COVID-19 pandemic has caused an alarming situation worldwide. Since the first detection, in December 2019, there have been no effective drug therapy options for treating the SARS-CoV-2 pandemic. However, healthcare professionals are using <b style='color:Tomato;'><i>chloroquine</i></b>, hydroxy<b style='color:Tomato;'><i>chloroquine</i></b>, <b style='color:Tomato;'><i>remdesivir</i></b>, convalescent plasma and some other options of treatments. <b style='color:DodgerBlue;'><i>This</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>aims</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>compare</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>biological</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>molecular</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>pharmacological</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>characteristics</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>these</i></b> <b style='color:DodgerBlue;'><i>three</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>modalities</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>SARS-COV-2</i></b> <b style='color:DodgerBlue;'><i>infections</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>Chloroquine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>Hydroxychloroquine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>Convalescent</i></b> <b style='color:DodgerBlue;'><i>Plasma</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>Remdesivir</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods A search was conducted in the "Institute of Science Information (ISI)-Web of Science, PubMed, EMBASE, ClinicalTrials.gov, Cochrane Library databases, Scopus, and Google Scholar" for peer reviewed, published studies and clinical trials through July 30, 2020. The search was based on keywords "COVID-19" SARS-COV-2, <b style='color:Tomato;'><i>chloroquine</i></b>, hydroxy<b style='color:Tomato;'><i>chloroquine</i></b>, convalescent plasma, <b style='color:Tomato;'><i>remdesivir</i></b> and treatment modalities. ### results As of July 30, 2020, a total of 36,640 relevant documents were published. From them 672 peer reviewed, published articles, and clinical trials were screened. We selected 17 relevant published original articles and clinical trials: 05 for <b style='color:Tomato;'><i>chloroquine</i></b> and/or hydroxy<b style='color:Tomato;'><i>chloroquine</i></b> with total sample size (n = 220), 05 for <b style='color:Tomato;'><i>remdesivir</i></b> (n = 1,781), and 07 for Convalescent Plasma therapy (n = 398), with a combined total sample size (n = 2,399). Based on the available data, convalescent plasma therapy showed clinical advantages in SARS-COV-2 patients. ### conclusions All three treatment modalities have both favorable and unfavorable characteristics, but none showed clear evidence of benefit for early outpatient disease or prophylaxis. Based on the current available data, convalescent plasma therapy appears to show clinical advantages for inpatient use. In the future, ongoing large sample size randomized controlled clinical trials may further clarify the comparative efficacy and safety of these three treatment classes, to conclusively determine whom to treat with which drug and when to treat them.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorA:</b>  The US Food and Drug Administration ( FDA ) recommends that " concomitant use of drugs that inhibit CYP2C19 ( e.g. ,  <span class="marker" data-anno-id="0" data-anno-label="N1">omeprazole</span>  ) should be discouraged . " As the presence of PPIs and  <span class="marker" data-anno-id="1" data-anno-label="N1">clopidogrel</span>  in plasma is short lived , separation by 12 - 20 h should in theory prevent competitive inhibition of CYP metabolism and minimize any potential , though unproven , clinical interaction . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorB:</b>  The US Food and Drug Administration ( FDA ) recommends that " concomitant use of drugs that inhibit CYP2C19 ( e.g. ,  <span class="marker" data-anno-id="0" data-anno-label="P1">omeprazole</span>  ) should be discouraged . " As the presence of PPIs and  <span class="marker" data-anno-id="1" data-anno-label="P1">clopidogrel</span>  in plasma is short lived , separation by 12 - 20 h should in theory prevent competitive inhibition of CYP metabolism and minimize any potential , though unproven , clinical interaction . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Proton pump inhibitor and clopidogrel interaction: fact or fiction?</u></h4>Current consensus recommendations state that patients prescribed <b style='color:Tomato;'><i>clopidogrel</i></b> plus <b style='color:Tomato;'><i>aspirin</i></b> should receive a proton pump inhibitor (PPI) to reduce gastrointestinal bleeding. <b style='color:Tomato;'><i>clopidogrel</i></b> is converted to its active metabolite by cytochrome P450 (CYP) enzymes. <b style='color:Tomato;'><i>clopidogrel</i></b> users with decreased CYP2C19 function have less inhibition of platelet aggregation and increased cardiovascular (CV) events. As PPI metabolism also involves CYP2C19, it was hypothesized that competition by PPIs might interfere with <b style='color:Tomato;'><i>clopidogrel</i></b>'s action. <b style='color:Tomato;'><i>omeprazole</i></b>, but not other PPIs, worsens surrogate markers of <b style='color:Tomato;'><i>clopidogrel</i></b> efficacy. Some (but not all) observational studies show that <b style='color:Tomato;'><i>clopidogrel</i></b> users prescribed PPIs have increased risks of CV events (hazard/odds ratios=1.25-1.5). When effect sizes are small to moderate (relative risks<1.5-2.0), however, it is only possible to conclude whether statistical associations are valid in randomized trials. A randomized trial of <b style='color:Tomato;'><i>omeprazole</i></b> vs. placebo in <b style='color:Tomato;'><i>clopidogrel</i></b> users showed no difference in CV events (hazard ratio=1.02,0.70-1.51). Thus, current evidence does not justify a conclusion that PPIs are associated with CV events among <b style='color:Tomato;'><i>clopidogrel</i></b> users, let alone a judgment of causality. Nonetheless, positive results from some observational studies and biological plausibility have led some health-care providers to accept that PPIs reduce <b style='color:Tomato;'><i>clopidogrel</i></b>'s efficacy. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>US</i></b> <b style='color:DodgerBlue;'><i>Food</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>Drug</i></b> <b style='color:DodgerBlue;'><i>Administration</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>FDA</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>recommends</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>"</i></b> <b style='color:DodgerBlue;'><i>concomitant</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>drugs</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>inhibit</i></b> <b style='color:DodgerBlue;'><i>CYP2C19</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>e.g.</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>omeprazole</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>should</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>discouraged</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>"</i></b> <b style='color:DodgerBlue;'><i>As</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>presence</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>PPIs</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>clopidogrel</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>plasma</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>short</i></b> <b style='color:DodgerBlue;'><i>lived</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>separation</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>12</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>20</i></b> <b style='color:DodgerBlue;'><i>h</i></b> <b style='color:DodgerBlue;'><i>should</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>theory</i></b> <b style='color:DodgerBlue;'><i>prevent</i></b> <b style='color:DodgerBlue;'><i>competitive</i></b> <b style='color:DodgerBlue;'><i>inhibition</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>CYP</i></b> <b style='color:DodgerBlue;'><i>metabolism</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>minimize</i></b> <b style='color:DodgerBlue;'><i>any</i></b> <b style='color:DodgerBlue;'><i>potential</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>though</i></b> <b style='color:DodgerBlue;'><i>unproven</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>interaction</i></b> <b style='color:DodgerBlue;'><i>.</i></b> PPI may be given before breakfast and <b style='color:Tomato;'><i>clopidogrel</i></b> at bedtime, or PPI may be taken before dinner and <b style='color:Tomato;'><i>clopidogrel</i></b> at lunchtime.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorA:</b>  We now present the long-term follow-up findings of a randomized phase III study on the addition of six cycles of  <span class="marker" data-anno-id="0" data-anno-label="P1">procarbazine</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="P1">lomustine</span>  , and  <span class="marker" data-anno-id="2" data-anno-label="P1">vincristine</span>  ( PCV ) chemotherapy to radiotherapy ( RT ) . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorB:</b>  We now present the long-term follow-up findings of a randomized phase III study on the addition of six cycles of  <span class="marker" data-anno-id="0" data-anno-label="P1">procarbazine</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="P1">lomustine</span>  , and  <span class="marker" data-anno-id="2" data-anno-label="P1">vincristine</span>  ( PCV ) chemotherapy to  <span class="marker" data-anno-id="3" data-anno-label="P1">radiotherapy</span>  ( RT ) . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.</u></h4>Anaplastic oligodendroglioma are chemotherapy-sensitive tumors. <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>now</i></b> <b style='color:DodgerBlue;'><i>present</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>long-term</i></b> <b style='color:DodgerBlue;'><i>follow-up</i></b> <b style='color:DodgerBlue;'><i>findings</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>randomized</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>III</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>addition</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>six</i></b> <b style='color:DodgerBlue;'><i>cycles</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>procarbazine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>lomustine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>PCV</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>radiotherapy</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>RT</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### Patients And Methods Adult patients with newly diagnosed anaplastic oligodendroglial tumors were randomly assigned to either 59.4 Gy of RT or the same RT followed by six cycles of adjuvant PCV. An exploratory analysis of the correlation between 1p/19q status and survival was part of the study. Retrospectively, the methylation status of the methyl-guanine methyl transferase gene promoter and the mutational status of the isocitrate dehydrogenase (IDH) gene were determined. The primary end points were overall survival (OS) and progression-free survival based on intent-to-treat analysis. ### results A total of 368 patients were enrolled. With a median follow-up of 140 months, OS in the RT/PCV arm was significantly longer (42.3 v 30.6 months in the RT arm, hazard ratio [HR], 0.75; 95% CI, 0.60 to 0.95). In the 80 patients with a 1p/19q codeletion, OS was increased, with a trend toward more benefit from adjuvant PCV (OS not reached in the RT/PCV group v 112 months in the RT group; HR, 0.56; 95% CI, 0.31 to 1.03). IDH mutational status was also of prognostic significance. ### conclusion The addition of six cycles of PCV after 59.4 Gy of RT increases both OS and PFS in anaplastic oligodendroglial tumors. 1p/19q-codeleted tumors derive more benefit from adjuvant PCV compared with non-1p/19q-deleted tumors.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorA:</b>  This was a multi-center randomized , two-armed , double-blinded phase II study comparing cediranib plus  <span class="marker" data-anno-id="0" data-anno-label="P1">gefitinib</span>  versus  <span class="marker" data-anno-id="1" data-anno-label="P1">cediranib</span>  plus placebo in subjects with first relapse/first progression of glioblastoma following surgery and chemoradiotherapy . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorB:</b>  This was a multi-center randomized , two-armed , double-blinded phase II study comparing  <span class="marker" data-anno-id="0" data-anno-label="P1">cediranib</span>  plus  <span class="marker" data-anno-id="1" data-anno-label="P1">gefitinib</span>  versus cediranib plus placebo in subjects with first relapse/first progression of glioblastoma following surgery and chemoradiotherapy . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma.</u></h4><b style='color:Tomato;'><i>cediranib</i></b>, an oral pan-vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor, failed to show benefit over <b style='color:Tomato;'><i>lomustine</i></b> in relapsed glioblastoma. One resistance mechanism for <b style='color:Tomato;'><i>cediranib</i></b> is up-regulation of epidermal growth factor receptor (EGFR). This study aimed to determine if dual therapy with <b style='color:Tomato;'><i>cediranib</i></b> and the oral EGFR inhibitor <b style='color:Tomato;'><i>gefitinib</i></b> improved outcome in recurrent glioblastoma. ### Methods And Findings <b style='color:DodgerBlue;'><i>This</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>multi-center</i></b> <b style='color:DodgerBlue;'><i>randomized</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>two-armed</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>double-blinded</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>II</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>comparing</i></b> <b style='color:MediumOrchid;'><i>cediranib</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>gefitinib</i></b> <b style='color:DodgerBlue;'><i>versus</i></b> <b style='color:MediumOrchid;'><i>cediranib</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:DodgerBlue;'><i>placebo</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>subjects</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>first</i></b> <b style='color:DodgerBlue;'><i>relapse/first</i></b> <b style='color:DodgerBlue;'><i>progression</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>glioblastoma</i></b> <b style='color:DodgerBlue;'><i>following</i></b> <b style='color:DodgerBlue;'><i>surgery</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>chemoradiotherapy</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The primary outcome measure was progression free survival (PFS). Secondary outcome measures included overall survival (OS) and radiologic response rate. Recruitment was terminated early following suspension of the <b style='color:Tomato;'><i>cediranib</i></b> program. 38 subjects (112 planned) were enrolled with 19 subjects in each treatment arm. Median PFS with <b style='color:Tomato;'><i>cediranib</i></b> plus <b style='color:Tomato;'><i>gefitinib</i></b> was 3.6 months compared to 2.8 months for <b style='color:Tomato;'><i>cediranib</i></b> plus placebo (HR; 0.72, 90% CI; 0.41 to 1.26). Median OS was 7.2 months with <b style='color:Tomato;'><i>cediranib</i></b> plus <b style='color:Tomato;'><i>gefitinib</i></b> and 5.5 months with <b style='color:Tomato;'><i>cediranib</i></b> plus placebo (HR; 0.68, 90% CI; 0.39 to 1.19). Eight subjects (42%) had a partial response in the <b style='color:Tomato;'><i>cediranib</i></b> plus <b style='color:Tomato;'><i>gefitinib</i></b> arm versus five patients (26%) in the <b style='color:Tomato;'><i>cediranib</i></b> plus placebo arm. ### conclusions <b style='color:Tomato;'><i>cediranib</i></b> and <b style='color:Tomato;'><i>gefitinib</i></b> in combination is tolerated in patients with glioblastoma. Incomplete recruitment led to the study being underpowered. However, a trend towards improved survival and response rates with the addition of <b style='color:Tomato;'><i>gefitinib</i></b> to <b style='color:Tomato;'><i>cediranib</i></b> was observed. Further studies of the combination incorporating EGFR and VEGF inhibition are warranted. ### Trial Registration ClinicalTrials.gov NCT01310855.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorA:</b>  Synergistic cytotoxic effects of recombinant  <span class="marker" data-anno-id="0" data-anno-label="P1/P2">human tumor necrosis factor</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">Etoposide</span>  ( VP16 ) or  <span class="marker" data-anno-id="2" data-anno-label="P2">Doxorubicin</span>  on A2774 human epithelial ovarian cancer cell line . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorB:</b>  Synergistic cytotoxic effects of recombinant human tumor necrosis factor and Etoposide ( VP16 ) or Doxorubicin on A2774 human epithelial ovarian cancer cell line . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u><b style='color:DodgerBlue;'><i>Synergistic</i></b> <b style='color:DodgerBlue;'><i>cytotoxic</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>recombinant</i></b> <b style='color:DodgerBlue;'><i>human</i></b> <b style='color:DodgerBlue;'><i>tumor</i></b> <b style='color:DodgerBlue;'><i>necrosis</i></b> <b style='color:DodgerBlue;'><i>factor</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>Etoposide</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>VP16</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>Doxorubicin</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>A2774</i></b> <b style='color:DodgerBlue;'><i>human</i></b> <b style='color:DodgerBlue;'><i>epithelial</i></b> <b style='color:DodgerBlue;'><i>ovarian</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>line</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h4>Recombinant human tumor necrosis factor (rHuTNF) is a cytokine, with some antitumor activity, released by stimulated monocytes-macrophages. In vivo and in vitro cytotoxicity studies testing the effectiveness of rHuTNF alone or in combination with chemotherapeutic agents have been carried out. We have evaluated the direct cytotoxic effect of rHuTNF on a human epithelial ovarian cancer cell line in vitro (A2774), alone or in combination with <b style='color:Tomato;'><i>etoposide</i></b> (VP16) or <b style='color:Tomato;'><i>doxorubicin</i></b> (Doxo), some topoisomerase II (Topo II) targeted drugs, or in combination with <b style='color:Tomato;'><i>cisplatin</i></b> (CDDP), a not Topo II interactive drug. Our results suggest that rHuTNF is directly cytotoxic and that it is also able to induce a potentiation of VP16- or Doxo-cytotoxicity, but it is unable to potentiate CDDP-cytotoxicity. These data represent a reasonable basis for combining rHuTNF with Topo II inhibitors within phase I studies. The combination regimen could be tested in ovarian cancer patients.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorA:</b>  This phase II study was performed to assess the efficacy and safety of the combination regimen of  <span class="marker" data-anno-id="0" data-anno-label="P1">temozolomide</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">docetaxel</span>  in patients with advanced metastatic melanoma . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorB:</b>  This phase II study was performed to assess the efficacy and safety of the combination regimen of temozolomide and docetaxel in patients with advanced metastatic melanoma . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group.</u></h4><b style='color:Tomato;'><i>temozolomide</i></b> is a novel oral alkylating agent that is effective against melanoma. Moreover, <b style='color:Tomato;'><i>temozolomide</i></b> readily crosses the blood-brain barrier and may consequently be effective in patients with brain metastases. <b style='color:DodgerBlue;'><i>This</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>II</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>performed</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>assess</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>safety</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>temozolomide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>melanoma</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### Patients And Methods Sixty-five patients with metastatic melanoma were enrolled. Treatment consisted of intravenous <b style='color:Tomato;'><i>docetaxel</i></b> (80 mg/m(2)) on day 1 and oral <b style='color:Tomato;'><i>temozolomide</i></b> (150 mg/m(2)) on days 1 to 5, every 4 weeks, for a maximum of six cycles. ### results Sixty-two patients were eligible for the efficacy and safety analysis. Seventeen patients (27%) achieved an objective response, including five complete (8%) and 12 partial responses (19%). Median response duration was 9.5 months. Among responders, median time to progression (TTP) was 11.2 months and median overall survival (OS) was 16 months. For all treated patients, the median TTP was 4 months and median OS was 11 months. Three (38%) of eight patients who presented with brain metastases had a partial response for 5, 6, and 12 months. Of 52 patients who did not have brain involvement at presentation, only four (8%) developed brain metastases at a median follow-up of 14 months. Myelosuppression was the primary toxicity. ### conclusion The combination of <b style='color:Tomato;'><i>temozolomide</i></b> and <b style='color:Tomato;'><i>docetaxel</i></b> was effective and well tolerated as first-line treatment for patients with advanced metastatic melanoma and demonstrated encouraging antitumor activity against brain metastases.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorA:</b>  Phase Ib Study of  <span class="marker" data-anno-id="0" data-anno-label="C1">Bavituximab</span>  With  <span class="marker" data-anno-id="1" data-anno-label="C1">Carboplatin</span>  and  <span class="marker" data-anno-id="2" data-anno-label="C1">Pemetrexed</span>  in Chemotherapy-Naive Advanced Nonsquamous Non-Small-Cell Lung Cancer . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorB:</b>  Phase Ib Study of Bavituximab With Carboplatin and Pemetrexed in Chemotherapy-Naive Advanced Nonsquamous Non-Small-Cell Lung Cancer . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u><b style='color:DodgerBlue;'><i>Phase</i></b> <b style='color:DodgerBlue;'><i>Ib</i></b> <b style='color:DodgerBlue;'><i>Study</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>Bavituximab</i></b> <b style='color:DodgerBlue;'><i>With</i></b> <b style='color:MediumOrchid;'><i>Carboplatin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>Pemetrexed</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>Chemotherapy-Naive</i></b> <b style='color:DodgerBlue;'><i>Advanced</i></b> <b style='color:DodgerBlue;'><i>Nonsquamous</i></b> <b style='color:DodgerBlue;'><i>Non-Small-Cell</i></b> <b style='color:DodgerBlue;'><i>Lung</i></b> <b style='color:DodgerBlue;'><i>Cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h4><b style='color:Tomato;'><i>bavituximab</i></b> is an immunomodulatory chimeric monoclonal antibody that inhibits phosphatidylserine signaling, which promotes innate and adaptive immune responses. In this phase Ib trial we evaluated the safety, tolerability, and preliminary antitumor activity of <b style='color:Tomato;'><i>pemetrexed</i></b>, <b style='color:Tomato;'><i>carboplatin</i></b>, <b style='color:Tomato;'><i>bavituximab</i></b> in advanced non-small-cell lung cancer (NSCLC). ### Patients And Methods Patients with advanced nonsquamous NSCLC and performance status 0 or 1 were treated with <b style='color:Tomato;'><i>pemetrexed</i></b> 500 mg/m ### results Between March 29, 2011 and December 30, 2013, 26 patients were enrolled. Three patients each were enrolled into dose escalation cohorts of <b style='color:Tomato;'><i>bavituximab</i></b> (0.3, 1, and 3 mg/kg). Therapy was well tolerated with no DLTs, and toxicities were consistent with those expected from <b style='color:Tomato;'><i>pemetrexed</i></b>/<b style='color:Tomato;'><i>carboplatin</i></b>. Overall response was 28%, with a median progression-free and overall survival of 4.8 months and 12.2 months, respectively. ### conclusion The combination of <b style='color:Tomato;'><i>pemetrexed</i></b>, <b style='color:Tomato;'><i>carboplatin</i></b>, <b style='color:Tomato;'><i>bavituximab</i></b> is well tolerated. However, with toxicities and preliminary efficacy signal similar to <b style='color:Tomato;'><i>pemetrexed</i></b>/<b style='color:Tomato;'><i>carboplatin</i></b> alone, further studies of <b style='color:Tomato;'><i>bavituximab</i></b> should focus on ways to enhance its immunomodulatory role.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorA:</b>  Treatment of unresectable GISTs involves systemic chemotherapy with tyrosine kinase inhibitors ,  <span class="marker" data-anno-id="0" data-anno-label="C1">imatinib</span>  and  <span class="marker" data-anno-id="1" data-anno-label="C1">sunitinib</span>  being first-line and second-line drugs . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorB:</b>  Treatment of unresectable GISTs involves systemic chemotherapy with tyrosine kinase inhibitors , imatinib and sunitinib being first-line and second-line drugs . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>A gastrointestinal stromal tumour with pulmonary metastases mimicking unilateral gynaecomastia.</u></h4>Gastrointestinal stromal tumours (GISTs) represent 1% of primary gastrointestinal cancers. These neoplasms most frequently metastasise to the liver and peritoneum and rarely to the lungs and bones. <b style='color:DodgerBlue;'><i>Treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>unresectable</i></b> <b style='color:DodgerBlue;'><i>GISTs</i></b> <b style='color:DodgerBlue;'><i>involves</i></b> <b style='color:DodgerBlue;'><i>systemic</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>tyrosine</i></b> <b style='color:DodgerBlue;'><i>kinase</i></b> <b style='color:DodgerBlue;'><i>inhibitors</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>imatinib</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>sunitinib</i></b> <b style='color:DodgerBlue;'><i>being</i></b> <b style='color:DodgerBlue;'><i>first-line</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>second-line</i></b> <b style='color:DodgerBlue;'><i>drugs</i></b> <b style='color:DodgerBlue;'><i>.</i></b> We report the case of a 52-year-old man with GIST who developed a right-sided subareolar breast swelling and subsequently discovered to be an invasive metastatic pulmonary GIST. Given that gynaecomastia is a known adverse effect of <b style='color:Tomato;'><i>imatinib</i></b> and <b style='color:Tomato;'><i>sunitinib</i></b>, this case report illustrates the importance of including metastatic disease in the differential diagnosis of patients with GIST and with the new onset of soft tissue masses.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorA:</b>  Increased dose density is feasible : a pilot study of adjuvant  <span class="marker" data-anno-id="0" data-anno-label="P1">epirubicin</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">cyclophosphamide</span>  followed by  <span class="marker" data-anno-id="2" data-anno-label="P2">paclitaxel</span>  , at 10- or 11-day intervals with  <span class="marker" data-anno-id="3" data-anno-label="P2">filgrastim</span>  support in women with breast cancer . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorB:</b>  Increased dose density is feasible : a pilot study of adjuvant  <span class="marker" data-anno-id="0" data-anno-label="P1">epirubicin</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">cyclophosphamide</span>  followed by  <span class="marker" data-anno-id="2" data-anno-label="P1">paclitaxel</span>  , at 10- or 11-day intervals with  <span class="marker" data-anno-id="3" data-anno-label="P1">filgrastim</span>  support in women with breast cancer . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u><b style='color:DodgerBlue;'><i>Increased</i></b> <b style='color:DodgerBlue;'><i>dose</i></b> <b style='color:DodgerBlue;'><i>density</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>feasible</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>pilot</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>adjuvant</i></b> <b style='color:MediumOrchid;'><i>epirubicin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>10-</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>11-day</i></b> <b style='color:DodgerBlue;'><i>intervals</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>filgrastim</i></b> <b style='color:DodgerBlue;'><i>support</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>women</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h4>Because Cancer and Leukemia Group B 9741 trial showed a benefit for every 14-day administration of chemotherapy compared with every 21-day treatment, we hypothesized that even greater dose density would be more effective. We conducted a pilot trial to assess the feasibility of dose-dense chemotherapy consisting of a standard regime at 10- to 11-day intervals in the adjuvant/neoadjuvant setting. A 2-day window was allowed for scheduling logistics. ### Experimental Design Thirty-nine women with early-stage breast carcinoma were accrued from April 2004 to October 2004. Median age was 47 years (range, 26-67 years). Patients received therapy with 100 mg/m(2) <b style='color:Tomato;'><i>epirubicin</i></b> and 600 mg/m(2) <b style='color:Tomato;'><i>cyclophosphamide</i></b> (EC) q 10 to 11 days for four cycles followed by 175 mg/m(2) <b style='color:Tomato;'><i>paclitaxel</i></b> q 10 to 11 days for four cycles, all with <b style='color:Tomato;'><i>filgrastim</i></b> support (300 microg s.c. daily) from day 2 to 24 h before the next treatment. ### results Thirty-five (90%) patients completed all planned therapy. The median intertreatment interval was 10 days (range, 8-28 days). Cycles (80.7%) were delivered at no more than 10- to 11-day intervals. There were five dose reductions of 25% for grade 3 nonhematologic toxicity in five patients. Six (16%) patients developed febrile neutropenia defined as temperature >38 degrees C with absolute neutrophil count <1,000/microL. All febrile neutropenia was during therapy with EC. Other grade 3 toxicities included bone pain, hand and foot syndrome, neuropathy, mucositis, nausea, and vomiting. ### conclusions Therapy with EC for four cycles followed by <b style='color:Tomato;'><i>paclitaxel</i></b> for four cycles at 10- to 11-day intervals is feasible. The approximately 30% reduction in intertreatment interval compared with every 14-day treatment could increase the efficacy of adjuvant chemotherapy.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorA:</b>  <span class="marker" data-anno-id="0" data-anno-label="C1">Heparin</span>  infusion , followed by oral  <span class="marker" data-anno-id="1" data-anno-label="C1">warfarin</span>  , is indicated for symptomatic thromboembolic disease as well as for asymptomatic patients with substantial proximal deep venous thrombosis or large pulmonary emboli . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorB:</b>  Heparin infusion , followed by oral warfarin , is indicated for symptomatic thromboembolic disease as well as for asymptomatic patients with substantial proximal deep venous thrombosis or large pulmonary emboli . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Therapy for postoperative thromboembolic disease:  indications and treatment.</u></h4>Postarthroplasty patients develop venous thromboembolic disease because of venous stasis, hypercoaguability, and vessel wall injury.  However, most venous thrombi are nonocclusive or small and elicit few symptoms; pulmonary emboli also tend to be asymptomatic.  Noninvasive techniques to detect deep vein thrombosis do not appear to be reliable in this population, so venography may be required.  Postoperative perfusion lung scans, with comparison to preoperative perfusion scans, are the best screen for asymptomatic pulmonary emboli. <b style='color:MediumOrchid;'><i>Heparin</i></b> <b style='color:DodgerBlue;'><i>infusion</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>oral</i></b> <b style='color:MediumOrchid;'><i>warfarin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>indicated</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>symptomatic</i></b> <b style='color:DodgerBlue;'><i>thromboembolic</i></b> <b style='color:DodgerBlue;'><i>disease</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>well</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>asymptomatic</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>substantial</i></b> <b style='color:DodgerBlue;'><i>proximal</i></b> <b style='color:DodgerBlue;'><i>deep</i></b> <b style='color:DodgerBlue;'><i>venous</i></b> <b style='color:DodgerBlue;'><i>thrombosis</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>large</i></b> <b style='color:DodgerBlue;'><i>pulmonary</i></b> <b style='color:DodgerBlue;'><i>emboli</i></b> <b style='color:DodgerBlue;'><i>.</i></b></div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorA:</b>  All patients were treated with  <span class="marker" data-anno-id="0" data-anno-label="P1">vincristine</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="P1">doxorubicin</span>  ,  <span class="marker" data-anno-id="2" data-anno-label="P1">cyclophosphamide</span>  and  <span class="marker" data-anno-id="3" data-anno-label="P1">actinomycin-D</span>  , alternating with  <span class="marker" data-anno-id="4" data-anno-label="P1">ifosfamide</span>  and  <span class="marker" data-anno-id="5" data-anno-label="P1">etoposide</span>  every 3 weeks . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorB:</b>  All patients were treated with  <span class="marker" data-anno-id="0" data-anno-label="C1">vincristine</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="C1">doxorubicin</span>  ,  <span class="marker" data-anno-id="2" data-anno-label="C1">cyclophosphamide</span>  and  <span class="marker" data-anno-id="3" data-anno-label="C1">actinomycin-D</span>  , alternating with  <span class="marker" data-anno-id="4" data-anno-label="C1">ifosfamide</span>  and  <span class="marker" data-anno-id="5" data-anno-label="C1">etoposide</span>  every 3 weeks . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Extraskeletal Ewing's sarcoma family of tumors in adults: prognostic factors and clinical outcome.</u></h4>The aim of this study was to evaluate prognostic factors, survival rate and the efficacy of the treatment modalities used in patients with extraskeletal Ewing's sarcoma. ### methods Data of patients with extraskeletal Ewing's sarcoma followed up at our center between 1997 and 2010 were retrospectively analyzed. ### results The median age of 27 patients was 24 years (range, 16-54 years). The median follow-up was 31.8 months (range, 6-144 months). Tumor size was between 1.5 and 14 cm (median: 8 cm). Eighty-five percent of patients had localized disease at presentation and 15% had metastatic disease. Local therapy was surgery alone in 16% of patients, surgery combined with radiotherapy in 42% and radiotherapy alone in 27%. <b style='color:DodgerBlue;'><i>All</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>actinomycin-D</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>alternating</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>ifosfamide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>etoposide</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In patients with localized disease at presentation, the 5-year event-free survival and overall survival were 59.7 and 64.5%, respectively. At univariate analysis, patients with tumor size ≥ 8 cm, high serum lactate dehydrogenase, metastasis at presentation, poor histological response to chemotherapy and positive surgical margin had significantly worse event-free survival. The significant predictors of worse overall survival at univariate analysis were tumor size 8 ≥ cm, high lactate dehydrogenase, metastasis at presentation, poor histological response to chemotherapy, radiotherapy only as local treatment and positive surgical margin. ### conclusions Prognostic factors were similar to primary osseous Ewing's sarcomas. Adequate surgical resection, aggressive chemotherapy (<b style='color:Tomato;'><i>vincristine</i></b>, <b style='color:Tomato;'><i>doxorubicin</i></b>, <b style='color:Tomato;'><i>cyclophosphamide</i></b> and actinomycin-D alternating with <b style='color:Tomato;'><i>ifosfamide</i></b> and <b style='color:Tomato;'><i>etoposide</i></b>) and radiotherapy if indicated are the recommended therapy for patients with extraskeletal Ewing's sarcoma.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorA:</b>  A total of 460 patients were randomized into four 10-day therapeutic schemes ( 115 patients per group ): ( i ) standard OCA , omeprazole , clarithromycin and amoxicillin ; ( ii ) triple OLA ,  <span class="marker" data-anno-id="0" data-anno-label="P1">omeprazole</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="P1">levofloxacin</span>  and  <span class="marker" data-anno-id="2" data-anno-label="P1">amoxicillin</span>  ; ( iii ) sequential OACM , omeprazole plus amoxicillin for 5 days , followed by omeprazole plus clarithromycin plus metronidazole for 5 days ; and ( iv ) modified sequential OALM , using levofloxacin instead of clarithromycin . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorB:</b>  A total of 460 patients were randomized into four 10-day therapeutic schemes ( 115 patients per group ): ( i ) standard OCA ,  <span class="marker" data-anno-id="0" data-anno-label="P1">omeprazole</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="P1">clarithromycin</span>  and  <span class="marker" data-anno-id="2" data-anno-label="P1">amoxicillin</span>  ; ( ii ) triple OLA ,  <span class="marker" data-anno-id="3" data-anno-label="P2">omeprazole</span>  ,  <span class="marker" data-anno-id="4" data-anno-label="P2">levofloxacin</span>  and  <span class="marker" data-anno-id="5" data-anno-label="P2">amoxicillin</span>  ; ( iii ) sequential OACM ,  <span class="marker" data-anno-id="6" data-anno-label="P3">omeprazole</span>  plus  <span class="marker" data-anno-id="7" data-anno-label="P3">amoxicillin</span>  for 5 days , followed by omeprazole plus  <span class="marker" data-anno-id="8" data-anno-label="P3">clarithromycin</span>  plus  <span class="marker" data-anno-id="9" data-anno-label="P3">metronidazole</span>  for 5 days ; and ( iv ) modified sequential OALM , using levofloxacin instead of clarithromycin . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradication.</u></h4>Helicobacter pylori eradication rates with standard triple therapy have declined to unacceptable levels. ### aim To compare <b style='color:Tomato;'><i>clarithromycin</i></b> and <b style='color:Tomato;'><i>levofloxacin</i></b> in triple and sequential first-line regimens. ### methods <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>total</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>460</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>randomized</i></b> <b style='color:DodgerBlue;'><i>into</i></b> <b style='color:DodgerBlue;'><i>four</i></b> <b style='color:DodgerBlue;'><i>10-day</i></b> <b style='color:DodgerBlue;'><i>therapeutic</i></b> <b style='color:DodgerBlue;'><i>schemes</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>115</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>per</i></b> <b style='color:DodgerBlue;'><i>group</i></b> <b style='color:DodgerBlue;'><i>):</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>i</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>standard</i></b> <b style='color:DodgerBlue;'><i>OCA</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>omeprazole</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>clarithromycin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>amoxicillin</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>ii</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>triple</i></b> <b style='color:DodgerBlue;'><i>OLA</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>omeprazole</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>levofloxacin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>amoxicillin</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>iii</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>sequential</i></b> <b style='color:DodgerBlue;'><i>OACM</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>omeprazole</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>amoxicillin</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:MediumOrchid;'><i>omeprazole</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>clarithromycin</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>metronidazole</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>iv</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>modified</i></b> <b style='color:DodgerBlue;'><i>sequential</i></b> <b style='color:DodgerBlue;'><i>OALM</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>using</i></b> <b style='color:MediumOrchid;'><i>levofloxacin</i></b> <b style='color:DodgerBlue;'><i>instead</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>clarithromycin</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Eradication was confirmed by 13C-urea breath test. Adverse effects and compliance were assessed by a questionnaire. ### results Per protocol cure rates were: OCA (66%; 95% CI: 57-74%), OLA (82.6%; 75-89%), OACM (80.8%; 73-88%) and OALM (85.2%; 78-91%). Intention-to-treat cure rates were: OCA (64%; 55-73%), OLA (80.8%; 73-88%), OACM (76.5%; 69-85%) and OALM (82.5%; 75-89%). Eradication rates were lower with OCA than with all the other regimens (P < 0.05). No differences in compliance or adverse effects were demonstrated among treatments. ### conclusions <b style='color:Tomato;'><i>levofloxacin</i></b>-based and sequential therapy are superior to standard triple scheme as first-line regimens in a setting with high <b style='color:Tomato;'><i>clarithromycin</i></b> resistance. However, all of these therapies still have a 20% failure rate.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorA:</b>  The standard adjuvant treatment of colon cancer is  <span class="marker" data-anno-id="0" data-anno-label="P1">fluorouracil</span>  plus  <span class="marker" data-anno-id="1" data-anno-label="P1">leucovorin</span>  ( FL ) . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorB:</b>  The standard adjuvant treatment of colon cancer is  <span class="marker" data-anno-id="0" data-anno-label="C1">fluorouracil</span>  plus  <span class="marker" data-anno-id="1" data-anno-label="C1">leucovorin</span>  ( FL ) . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.</u></h4> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>standard</i></b> <b style='color:DodgerBlue;'><i>adjuvant</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>colon</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:MediumOrchid;'><i>fluorouracil</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>leucovorin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>FL</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:Tomato;'><i>oxaliplatin</i></b> improves the efficacy of this combination in patients with metastatic colorectal cancer. We evaluated the efficacy of treatment with FL plus <b style='color:Tomato;'><i>oxaliplatin</i></b> in the postoperative adjuvant setting. ### methods We randomly assigned 2246 patients who had undergone curative resection for stage II or III colon cancer to receive FL alone or with <b style='color:Tomato;'><i>oxaliplatin</i></b> for six months. The primary end point was disease-free survival. ### results A total of 1123 patients were randomly assigned to each group. After a median follow-up of 37.9 months, 237 patients in the group given FL plus <b style='color:Tomato;'><i>oxaliplatin</i></b> had had a cancer-related event, as compared with 293 patients in the FL group (21.1 percent vs. 26.1 percent; hazard ratio for recurrence, 0.77; P=0.002). The rate of disease-free survival at three years was 78.2 percent (95 percent confidence interval, 75.6 to 80.7) in the group given FL plus <b style='color:Tomato;'><i>oxaliplatin</i></b> and 72.9 percent (95 percent confidence interval, 70.2 to 75.7) in the FL group (P=0.002 by the stratified log-rank test). In the group given FL plus <b style='color:Tomato;'><i>oxaliplatin</i></b>, the incidence of febrile neutropenia was 1.8 percent, the incidence of gastrointestinal adverse effects was low, and the incidence of grade 3 sensory neuropathy was 12.4 percent during treatment, decreasing to 1.1 percent at one year of follow-up. Six patients in each group died during treatment (death rate, 0.5 percent). ### conclusions Adding <b style='color:Tomato;'><i>oxaliplatin</i></b> to a regimen of <b style='color:Tomato;'><i>fluorouracil</i></b> and <b style='color:Tomato;'><i>leucovorin</i></b> improves the adjuvant treatment of colon cancer.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorA:</b>  <span class="marker" data-anno-id="0" data-anno-label="C1">Abiraterone</span>  acetate and  <span class="marker" data-anno-id="1" data-anno-label="C1">prednisone</span>  in the pre- and post-docetaxel setting for metastatic castration-resistant prostate cancer : a mono-institutional experience focused on cardiovascular events and their impact on clinical outcomes . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorB:</b>  <span class="marker" data-anno-id="0" data-anno-label="P1">Abiraterone</span>  acetate and  <span class="marker" data-anno-id="1" data-anno-label="P1">prednisone</span>  in the pre- and post-docetaxel setting for metastatic castration-resistant prostate cancer : a mono-institutional experience focused on cardiovascular events and their impact on clinical outcomes . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u><b style='color:MediumOrchid;'><i>Abiraterone</i></b> <b style='color:DodgerBlue;'><i>acetate</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>prednisone</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>pre-</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>post-docetaxel</i></b> <b style='color:DodgerBlue;'><i>setting</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>castration-resistant</i></b> <b style='color:DodgerBlue;'><i>prostate</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>mono-institutional</i></b> <b style='color:DodgerBlue;'><i>experience</i></b> <b style='color:DodgerBlue;'><i>focused</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>cardiovascular</i></b> <b style='color:DodgerBlue;'><i>events</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>their</i></b> <b style='color:DodgerBlue;'><i>impact</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>outcomes</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h4>The aim of this work was to to evaluate the incidence and risk factors of adverse events (AEs), focusing on cardiovascular events (CVEs) and hypokalemia, in patients treated with <b style='color:Tomato;'><i>abiraterone</i></b> acetate (AA) and <b style='color:Tomato;'><i>prednisone</i></b> (PDN) outside clinical trials, and their association with survival outcomes. ### methods This was a retrospective cohort study of 105 patients treated from 2011 to 2016. Incidence of AEs was descriptively summarized in the whole cohort and by subgroup (pre- ### results Overall, median PFS and OS were 14.9 and 24.6 months, respectively. Prostate-specific antigen (PSA) ⩾ 10 ng/ml ( ### conclusions Median PFS and OS estimates and incidence of CVEs and hypokalemia in our series are consistent with those of pivotal trials of AA plus PDN, confirming the efficacy and safety of this regimen also in the real-world setting. Elderly patients have higher odds of developing/worsening CVEs. However, regardless of age, CVEs were not associated with worse outcomes. Treatment-related hypokalemia seemed to be associated with longer OS, albeit this finding needs confirmation within larger, prospective series.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorA:</b>  We studied the combination of  <span class="marker" data-anno-id="0" data-anno-label="P1">pemetrexed</span>  , a multi-targeted antifolate , and  <span class="marker" data-anno-id="1" data-anno-label="P1">cetuximab</span>  , an mAb against the epidermal growth factor receptor , with radiotherapy in poor prognosis head and neck cancer . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorB:</b>  We studied the combination of  <span class="marker" data-anno-id="0" data-anno-label="C1">pemetrexed</span>  , a multi-targeted antifolate , and  <span class="marker" data-anno-id="1" data-anno-label="C1">cetuximab</span>  , an mAb against the epidermal growth factor receptor , with radiotherapy in poor prognosis head and neck cancer . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Phase I trial of pemetrexed in combination with cetuximab and concurrent radiotherapy in patients with head and neck cancer.</u></h4> <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>studied</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>pemetrexed</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>multi-targeted</i></b> <b style='color:DodgerBlue;'><i>antifolate</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>cetuximab</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>mAb</i></b> <b style='color:DodgerBlue;'><i>against</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>epidermal</i></b> <b style='color:DodgerBlue;'><i>growth</i></b> <b style='color:DodgerBlue;'><i>factor</i></b> <b style='color:DodgerBlue;'><i>receptor</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>radiotherapy</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>poor</i></b> <b style='color:DodgerBlue;'><i>prognosis</i></b> <b style='color:DodgerBlue;'><i>head</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>neck</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### Patients And Methods Patients received <b style='color:Tomato;'><i>pemetrexed</i></b> on days 1, 22, and 43 on a dose-escalation scheme with starting level (0) 350 mg/m(2) (level -1, 200 mg/m(2); level +1, 500 mg/m(2)) with concurrent radiotherapy (2 Gy/day) and <b style='color:Tomato;'><i>cetuximab</i></b> in two separate cohorts, not previously irradiated (A) and previously irradiated (B), who received 70 and 60-66 Gy, respectively. Genetic polymorphisms of thymidylate synthase and methylenetetrahydrofolate reductase were evaluated. ### results Thirty-two patients were enrolled. The maximum tolerated dose of <b style='color:Tomato;'><i>pemetrexed</i></b> was 500 mg/m(2) in cohort A and 350 mg/m(2) in cohort B. Prophylactic antibiotics were required. In cohort A, two dose-limiting toxicities (DLTs) occurred (febrile neutropenia), one each at levels 0 and +1. In cohort B, two DLTs occurred at level +1 (febrile neutropenia; death from perforated duodenal ulcer and sepsis). Grade 3 mucositis was common. No association of gene polymorphisms with toxicity or efficacy was evident. ### conclusion The addition of <b style='color:Tomato;'><i>pemetrexed</i></b> 500 mg/m(2) to <b style='color:Tomato;'><i>cetuximab</i></b> and radiotherapy is recommended for further study in not previously irradiated patients.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorA:</b>  Targeted therapy was administered to match the P1K3CA , c-MET , and SPARC and COX2 aberrations with  <span class="marker" data-anno-id="0" data-anno-label="N1">sirolimus+ crizotinib</span>  and  <span class="marker" data-anno-id="1" data-anno-label="N2">abraxane+ celecoxib</span>  . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorB:</b>  Targeted therapy was administered to match the P1K3CA , c-MET , and SPARC and COX2 aberrations with  <span class="marker" data-anno-id="0" data-anno-label="C1">sirolimus+ crizotinib</span>  and  <span class="marker" data-anno-id="1" data-anno-label="C2">abraxane+ celecoxib</span>  . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Personalized comprehensive molecular profiling of high risk osteosarcoma: Implications and limitations for precision medicine.</u></h4>Despite advances in molecular medicine over recent decades, there has been little advancement in the treatment of osteosarcoma. We performed comprehensive molecular profiling in two cases of metastatic and chemotherapy-refractory osteosarcoma to guide molecularly targeted therapy. ### Patients And Methods Hybridization capture of >300 cancer-related genes plus introns from 28 genes often rearranged or altered in cancer was applied to >50 ng of DNA extracted from tumor samples from two patients with recurrent, metastatic osteosarcoma. The DNA from each sample was sequenced to high, uniform coverage. Immunohistochemical probes and morphoproteomics analysis were performed, in addition to fluorescence in situ hybridization. All analyses were performed in CLIA-certified laboratories. Molecularly targeted therapy based on the resulting profiles was offered to the patients. Biomedical analytics were performed using QIAGEN's Ingenuity® Pathway Analysis. ### results In Patient #1, comprehensive next-generation exome sequencing showed MET amplification, PIK3CA mutation, CCNE1 amplification, and PTPRD mutation. Immunohistochemistry-based morphoproteomic analysis revealed c-Met expression [(p)-c-Met (Tyr1234/1235)] and activation of mTOR/AKT pathway [IGF-1R (Tyr1165/1166), p-mTOR [Ser2448], p-Akt (Ser473)] and expression of SPARC and COX2. <b style='color:DodgerBlue;'><i>Targeted</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>administered</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>match</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>P1K3CA</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>c-MET</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>SPARC</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>COX2</i></b> <b style='color:DodgerBlue;'><i>aberrations</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>sirolimus+</i></b> <b style='color:MediumOrchid;'><i>crizotinib</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>abraxane+</i></b> <b style='color:MediumOrchid;'><i>celecoxib</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In Patient #2, aberrations included NF2 loss in exons 2-16, PDGFRα amplification, and TP53 mutation. This patient was enrolled on a clinical trial combining targeted agents tem<b style='color:Tomato;'><i>sirolimus</i></b>, <b style='color:Tomato;'><i>sorafenib</i></b> and <b style='color:Tomato;'><i>bevacizumab</i></b>, to match NF2, PDGFRα and TP53 aberrations. Both the patients did not benefit from matched therapy. ### conclusions Relapsed osteosarcoma is characterized by complex signaling and drug resistance pathways. Comprehensive molecular profiling holds great promise for tailoring personalized therapies for cancer. Methods for such profiling are evolving and need to be refined to better assist clinicians in making treatment decisions based on the large amount of data that results from this type of testing. Further research in this area is warranted.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorA:</b>  Addition of  <span class="marker" data-anno-id="0" data-anno-label="C1">verapamil</span>  and  <span class="marker" data-anno-id="1" data-anno-label="C1">tamoxifen</span>  to the initial chemotherapy of small cell lung cancer . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorB:</b>  Addition of  <span class="marker" data-anno-id="0" data-anno-label="P1">verapamil</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">tamoxifen</span>  to the initial chemotherapy of small cell lung cancer . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u><b style='color:DodgerBlue;'><i>Addition</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>verapamil</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>tamoxifen</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>initial</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>small</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>lung</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h4>Based on experimental observations that <b style='color:Tomato;'><i>verapamil</i></b> and <b style='color:Tomato;'><i>tamoxifen</i></b> reverse multiple drug resistance, the authors investigated the feasibility of combining both agents with the initial chemotherapy of extensive small cell lung cancer. Overall, in a consecutive series of 58 patients the most important toxicity was myelosuppression, and there was a 24% rate of severe infections. Therapeutic results included 24% complete and 34% partial response rates, median time to disease progression of 32 weeks, and median survival of 46 weeks. In three consecutive cohorts of patients the dose of either <b style='color:Tomato;'><i>tamoxifen</i></b> or <b style='color:Tomato;'><i>verapamil</i></b> were escalated by 25% and 33%, respectively. The cohort of patients receiving <b style='color:Tomato;'><i>verapamil</i></b> 360 mg/day and <b style='color:Tomato;'><i>tamoxifen</i></b> 100 mg/day (level 2) had slightly more toxicity but also more responses than the other groups. Therefore, the authors recommend that these doses be used in controlled trials to confirm the promising results of their study.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorA:</b>  Such therapy has included weekly  <span class="marker" data-anno-id="0" data-anno-label="P2/P1">paclitaxel</span>  in combination with  <span class="marker" data-anno-id="1" data-anno-label="P1">carboplatin/cisplatin</span>  plus  <span class="marker" data-anno-id="2" data-anno-label="P1">topotecan</span>  , and  <span class="marker" data-anno-id="3" data-anno-label="P2">carboplatin</span>  plus  <span class="marker" data-anno-id="4" data-anno-label="P2">doxorubicin</span>  . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorB:</b>  Such therapy has included weekly  <span class="marker" data-anno-id="0" data-anno-label="C1">paclitaxel</span>  in combination with  <span class="marker" data-anno-id="1" data-anno-label="C1">carboplatin/cisplatin</span>  plus  <span class="marker" data-anno-id="2" data-anno-label="C1">topotecan</span>  , and  <span class="marker" data-anno-id="3" data-anno-label="C2">carboplatin</span>  plus  <span class="marker" data-anno-id="4" data-anno-label="C2">doxorubicin</span>  . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Role of weekly paclitaxel in the treatment of advanced ovarian cancer.</u></h4>Dose-dense weekly administration of <b style='color:Tomato;'><i>paclitaxel</i></b> has the potential advantage of allowing a larger percentage of cancer cells to enter the vulnerable phase of their cell cycle when cytotoxic <b style='color:Tomato;'><i>paclitaxel</i></b> concentrations are present. The lower doses and shorter infusion times used with weekly dosing should also minimize bone marrow suppression and other toxicities associated with standard <b style='color:Tomato;'><i>paclitaxel</i></b> 3-weekly administration. Clinical studies have confirmed that <b style='color:Tomato;'><i>paclitaxel</i></b> can be safely delivered on a weekly schedule as a 1-h infusion to patients with advanced ovarian cancer. Weekly administration of <b style='color:Tomato;'><i>paclitaxel</i></b> also appears to be better tolerated than 3-weekly administration. Single-agent weekly <b style='color:Tomato;'><i>paclitaxel</i></b> is associated with response rates of 20-65%. Combination therapy with weekly <b style='color:Tomato;'><i>paclitaxel</i></b> has mainly involved <b style='color:Tomato;'><i>carboplatin</i></b> and response rates with such regimens range from 60-88%. Triple-drug combination therapy has produced response rates of 42-67.5%. <b style='color:DodgerBlue;'><i>Such</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>included</i></b> <b style='color:DodgerBlue;'><i>weekly</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>carboplatin/cisplatin</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>topotecan</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In an attempt to avoid problems with high corticosteroid doses, <b style='color:Tomato;'><i>dexamethasone</i></b> doses of 10 and 8 mg have been used successfully in premedication regimens for weekly <b style='color:Tomato;'><i>paclitaxel</i></b> in ovarian cancer.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorA:</b>  Boosting  <span class="marker" data-anno-id="0" data-anno-label="P1">darunavir</span>  with  <span class="marker" data-anno-id="1" data-anno-label="P1">ritonavir</span>  instead of with cobicistat may be preferred if darunavir is to be combined with  <span class="marker" data-anno-id="2" data-anno-label="P1">etravirine</span>  in clinical practice . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorB:</b>  Boosting  <span class="marker" data-anno-id="0" data-anno-label="P1">darunavir</span>  with  <span class="marker" data-anno-id="1" data-anno-label="P1">ritonavir</span>  instead of with cobicistat may be preferred if  <span class="marker" data-anno-id="2" data-anno-label="P2">darunavir</span>  is to be combined with  <span class="marker" data-anno-id="3" data-anno-label="P2">etravirine</span>  in clinical practice . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Pharmacokinetics of darunavir/cobicistat and etravirine alone and co-administered in HIV-infected patients.</u></h4>To determine the effect of <b style='color:Tomato;'><i>etravirine</i></b> on the pharmacokinetics of <b style='color:Tomato;'><i>darunavir</i></b>/<b style='color:Tomato;'><i>cobicistat</i></b> and vice versa. Safety and tolerability of this combination were also evaluated. ### methods Open-label, fixed-sequence trial in two cohorts of HIV-infected patients on therapy with <b style='color:Tomato;'><i>darunavir</i></b>/<b style='color:Tomato;'><i>cobicistat</i></b> 800/150 mg once daily (DRV cohort; n = 15) or <b style='color:Tomato;'><i>etravirine</i></b> 400 mg once daily (ETR cohort; n = 15). <b style='color:Tomato;'><i>etravirine</i></b> or <b style='color:Tomato;'><i>darunavir</i></b>/<b style='color:Tomato;'><i>cobicistat</i></b> were added on days 1-14 and 1-7 in participants in the DRV or ETR cohort, respectively. Full pharmacokinetic profiles were obtained on days 0 and 14 in the DRV cohort, and on days 0 and 7 in the ETR cohort. <b style='color:Tomato;'><i>darunavir</i></b>, <b style='color:Tomato;'><i>cobicistat</i></b> and <b style='color:Tomato;'><i>etravirine</i></b> pharmacokinetic parameters [AUC0-24, Cmax and trough concentrations in plasma (C24)] were calculated for each individual by non-compartmental analysis and were compared using linear mixed-effects models. Adverse events and HIV-1 RNA in plasma were monitored. ### results <b style='color:Tomato;'><i>etravirine</i></b> co-administration decreased <b style='color:Tomato;'><i>cobicistat</i></b> AUC0-24, Cmax and C24 by 30%, 14% and 66%, respectively. Although <b style='color:Tomato;'><i>darunavir</i></b> AUC0-24 and Cmax were unchanged by <b style='color:Tomato;'><i>etravirine</i></b>, <b style='color:Tomato;'><i>darunavir</i></b> C24 was 56% lower for <b style='color:Tomato;'><i>darunavir</i></b>/<b style='color:Tomato;'><i>cobicistat</i></b> co-administered with <b style='color:Tomato;'><i>etravirine</i></b> relative to <b style='color:Tomato;'><i>darunavir</i></b>/<b style='color:Tomato;'><i>cobicistat</i></b> alone. <b style='color:Tomato;'><i>etravirine</i></b> pharmacokinetics were unchanged by <b style='color:Tomato;'><i>darunavir</i></b>/<b style='color:Tomato;'><i>cobicistat</i></b>. Treatments were well tolerated, and HIV-1 RNA remained undetectable in all participants. ### conclusions Although <b style='color:Tomato;'><i>etravirine</i></b> pharmacokinetics was unchanged by <b style='color:Tomato;'><i>darunavir</i></b>/<b style='color:Tomato;'><i>cobicistat</i></b>, there was a significant decrease in <b style='color:Tomato;'><i>cobicistat</i></b> exposure and in <b style='color:Tomato;'><i>darunavir</i></b> C24 when <b style='color:Tomato;'><i>darunavir</i></b>/<b style='color:Tomato;'><i>cobicistat</i></b> was co-administered with <b style='color:Tomato;'><i>etravirine</i></b>. <b style='color:DodgerBlue;'><i>Boosting</i></b> <b style='color:MediumOrchid;'><i>darunavir</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>ritonavir</i></b> <b style='color:DodgerBlue;'><i>instead</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>cobicistat</i></b> <b style='color:DodgerBlue;'><i>may</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>preferred</i></b> <b style='color:DodgerBlue;'><i>if</i></b> <b style='color:MediumOrchid;'><i>darunavir</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>etravirine</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>practice</i></b> <b style='color:DodgerBlue;'><i>.</i></b></div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorA:</b>  Prognostic value of expression of Kit67 , p53 , TopoIIa and GSTP1 for curatively resected advanced gastric cancer patients receiving adjuvant  <span class="marker" data-anno-id="0" data-anno-label="C1">paclitaxel</span>  plus  <span class="marker" data-anno-id="1" data-anno-label="C1">capecitabine</span>  chemotherapy . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorB:</b>  Prognostic value of expression of Kit67 , p53 , TopoIIa and GSTP1 for curatively resected advanced gastric cancer patients receiving adjuvant  <span class="marker" data-anno-id="0" data-anno-label="P1">paclitaxel</span>  plus  <span class="marker" data-anno-id="1" data-anno-label="P1">capecitabine</span>  chemotherapy . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u><b style='color:DodgerBlue;'><i>Prognostic</i></b> <b style='color:DodgerBlue;'><i>value</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>expression</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>Kit67</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>p53</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>TopoIIa</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>GSTP1</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>curatively</i></b> <b style='color:DodgerBlue;'><i>resected</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>gastric</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>receiving</i></b> <b style='color:DodgerBlue;'><i>adjuvant</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>capecitabine</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h4>To investigate the role of Kit67, p53, topoisomerase II (TopoII) and glutathione S-transferase P1 (GSTP1) in predicting clinical outcome of advanced gastric cancer patients receiving <b style='color:Tomato;'><i>capecitabine</i></b> plus <b style='color:Tomato;'><i>paclitaxel</i></b> chemotherapy. ### methodology The clinical data and tissue samples from 136 curatively resected advanced gastric cancer patients receiving <b style='color:Tomato;'><i>capecitabine</i></b> plus <b style='color:Tomato;'><i>paclitaxel</i></b> in the third affiliated hospital of Kunming medical university from January 2005 to December 2007 were retrospectively collected and analyzed for Kit67, p53, TopoIIa and GSTP1 expressions by immunohistochemistry. The relationships between expressions of the biomarkers and survival were analyzed. ### results p53 expression were associated with the significantly shorter disease-free survival (DFS) (p<0.001) and overall survival (OS) (p=0.012) in the curatively resected advanced gastric cancer patients receiving <b style='color:Tomato;'><i>capecitabine</i></b> plus <b style='color:Tomato;'><i>paclitaxel</i></b>. Kit67, TopoIIa and GSTP1 expressions were not related to DFS and OS. ### conclusions p53 expression positive might predict prognosis in gastric cancer patients who underwent curative surgery followed by adjuvant <b style='color:Tomato;'><i>capecitabine</i></b> plus <b style='color:Tomato;'><i>paclitaxel</i></b> chemotherapy. A favorable effect of <b style='color:Tomato;'><i>capecitabine</i></b> plus <b style='color:Tomato;'><i>paclitaxel</i></b> might therefore be expected in patients that do not express p53.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorA:</b>  Nal-IRI with  <span class="marker" data-anno-id="0" data-anno-label="C1">5-fluorouracil</span>  ( 5-FU ) and  <span class="marker" data-anno-id="1" data-anno-label="C1">leucovorin</span>  or  <span class="marker" data-anno-id="2" data-anno-label="C2">gemcitabine</span>  plus  <span class="marker" data-anno-id="3" data-anno-label="C2">cisplatin</span>  in advanced biliary tract cancer - the NIFE trial ( AIO-YMO HEP-0315 ) </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorB:</b>  <span class="marker" data-anno-id="0" data-anno-label="C1">Nal-IRI</span>  with  <span class="marker" data-anno-id="1" data-anno-label="C1">5-fluorouracil</span>  ( 5-FU ) and  <span class="marker" data-anno-id="2" data-anno-label="C1">leucovorin</span>  or  <span class="marker" data-anno-id="3" data-anno-label="C2">gemcitabine</span>  plus  <span class="marker" data-anno-id="4" data-anno-label="C2">cisplatin</span>  in advanced biliary tract cancer - the NIFE trial ( AIO-YMO HEP-0315 ) </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u><b style='color:DodgerBlue;'><i>Nal-IRI</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>5-fluorouracil</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>5-FU</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>leucovorin</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>gemcitabine</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>biliary</i></b> <b style='color:DodgerBlue;'><i>tract</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>NIFE</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>AIO-YMO</i></b> <b style='color:DodgerBlue;'><i>HEP-0315</i></b> <b style='color:DodgerBlue;'><i>)</i></b></u></h4>Biliary tract cancer (BTC) has a high mortality. Primary diagnosis is frequently delayed due to mostly unspecific symptoms, resulting in a high number of advanced cases at the time of diagnosis. Advanced BTCs are in principle chemotherapy sensitive as determined by improved disease control, survival and quality of life (QoL). However, median OS does not exceed 11.7 months with the current standard of care <b style='color:Tomato;'><i>gemcitabine</i></b> plus <b style='color:Tomato;'><i>cisplatin</i></b>. Thereby, novel drug formulations like nanoliposomal-<b style='color:Tomato;'><i>irinotecan</i></b> (nal-IRI) in combination with 5- <b style='color:Tomato;'><i>fluorouracil</i></b> (5-FU)/<b style='color:Tomato;'><i>leucovorin</i></b> may have the potential to improve therapeutic outcomes in this disease. ### methods NIFE is an interventional, prospective, randomized, controlled, open label, two-sided phase II study. Within the study, 2 × 46 patients with locally advanced, non-resectable or metastatic BTC are to be enrolled by two stage design of Simon. Data analysis will be done unconnected for both arms. Patients are allocated in two arms: Arm A (experimental intervention) nal-IRI mg/m ### discussion The NIFE trial evaluates the potential of a nanoliposomal-<b style='color:Tomato;'><i>irinotecan</i></b>/5-FU/<b style='color:Tomato;'><i>leucovorin</i></b> combination in the first line therapy of advanced BTCs and additionally offers a unique chance for translational research. ### Trial Registration Clinicaltrials.gov NCT03044587. Registration Date February 7th 2017.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorA:</b>  EURAMOS-1 results do not support the addition of  <span class="marker" data-anno-id="0" data-anno-label="N1">ifosfamide</span>  and  <span class="marker" data-anno-id="1" data-anno-label="N1">etoposide</span>  to  <span class="marker" data-anno-id="2" data-anno-label="N1">postoperative chemotherapy</span>  in patients with poorly responding osteosarcoma because its administration was associated with increased toxicity without improving event-free survival . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorB:</b>  EURAMOS-1 results do not support the addition of  <span class="marker" data-anno-id="0" data-anno-label="N1">ifosfamide</span>  and  <span class="marker" data-anno-id="1" data-anno-label="N1">etoposide</span>  to postoperative chemotherapy in patients with poorly responding osteosarcoma because its administration was associated with increased toxicity without improving event-free survival . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial.</u></h4>We designed the EURAMOS-1 trial to investigate whether intensified postoperative chemotherapy for patients whose tumour showed a poor response to preoperative chemotherapy (≥10% viable tumour) improved event-free survival in patients with high-grade osteosarcoma. ### methods EURAMOS-1 was an open-label, international, phase 3 randomised, controlled trial. Consenting patients with newly diagnosed, resectable, high-grade osteosarcoma aged 40 years or younger were eligible for randomisation. Patients were randomly assigned (1:1) to receive either postoperative <b style='color:Tomato;'><i>cisplatin</i></b>, <b style='color:Tomato;'><i>doxorubicin</i></b>, and <b style='color:Tomato;'><i>methotrexate</i></b> (MAP) or MAP plus <b style='color:Tomato;'><i>ifosfamide</i></b> and <b style='color:Tomato;'><i>etoposide</i></b> (MAPIE) using concealed permuted blocks with three stratification factors: trial group; location of tumour (proximal femur or proximal humerus vs other limb vs axial skeleton); and presence of metastases (no vs yes or possible). The MAP regimen consisted of <b style='color:Tomato;'><i>cisplatin</i></b> 120 mg/m ### findings Between April 14, 2005, and June 30, 2011, 2260 patients were registered from 325 sites in 17 countries. 618 patients with poor response were randomly assigned; 310 to receive MAP and 308 to receive MAPIE. Median follow-up was 62·1 months (IQR 46·6-76·6); 62·3 months (IQR 46·9-77·1) for the MAP group and 61·1 months (IQR 46·5-75·3) for the MAPIE group. 307 event-free survival events were reported (153 in the MAP group vs 154 in the MAPIE group). 193 deaths were reported (101 in the MAP group vs 92 in the MAPIE group). Event-free survival did not differ between treatment groups (hazard ratio [HR] 0·98 [95% CI 0·78-1·23]); hazards were non-proportional (p=0·0003). The most common grade 3-4 adverse events were neutropenia (268 [89%] patients in MAP vs 268 [90%] in MAPIE), thrombocytopenia (231 [78% in MAP vs 248 [83%] in MAPIE), and febrile neutropenia without documented infection (149 [50%] in MAP vs 217 [73%] in MAPIE). MAPIE was associated with more frequent grade 4 non-haematological toxicity than MAP (35 [12%] of 301 in the MAP group vs 71 [24%] of 298 in the MAPIE group). Two patients died during postoperative therapy, one from infection (although their absolute neutrophil count was normal), which was definitely related to their MAP treatment (specifically <b style='color:Tomato;'><i>doxorubicin</i></b> and <b style='color:Tomato;'><i>cisplatin</i></b>), and one from left ventricular systolic dysfunction, which was probably related to MAPIE treatment (specifically <b style='color:Tomato;'><i>doxorubicin</i></b>). One suspected unexpected serious adverse reaction was reported in the MAP group: bone marrow infarction due to <b style='color:Tomato;'><i>methotrexate</i></b>. ### interpretation <b style='color:DodgerBlue;'><i>EURAMOS-1</i></b> <b style='color:DodgerBlue;'><i>results</i></b> <b style='color:DodgerBlue;'><i>do</i></b> <b style='color:DodgerBlue;'><i>not</i></b> <b style='color:DodgerBlue;'><i>support</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>addition</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>ifosfamide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>etoposide</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>postoperative</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>poorly</i></b> <b style='color:DodgerBlue;'><i>responding</i></b> <b style='color:DodgerBlue;'><i>osteosarcoma</i></b> <b style='color:DodgerBlue;'><i>because</i></b> <b style='color:DodgerBlue;'><i>its</i></b> <b style='color:DodgerBlue;'><i>administration</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>associated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>increased</i></b> <b style='color:DodgerBlue;'><i>toxicity</i></b> <b style='color:DodgerBlue;'><i>without</i></b> <b style='color:DodgerBlue;'><i>improving</i></b> <b style='color:DodgerBlue;'><i>event-free</i></b> <b style='color:DodgerBlue;'><i>survival</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The results define standard of care for this population. New strategies are required to improve outcomes in this setting. ### funding UK Medical Research Council, National Cancer Institute, European Science Foundation, St Anna Kinderkrebsforschung, Fonds National de la Recherche Scientifique, Fonds voor Wetenschappelijk Onderzoek-Vlaanderen, Parents Organization, Danish Medical Research Council, Academy of Finland, Deutsche Forschungsgemeinschaft, Deutsche Krebshilfe, Federal Ministry of Education and Research, Semmelweis Foundation, ZonMw (Council for Medical Research), Research Council of Norway, Scandinavian Sarcoma Group, Swiss Paediatric Oncology Group, Cancer Research UK, National Institute for Health Research, University College London Hospitals, and Biomedical Research Centre.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorA:</b>  These results confirm that sequential  <span class="marker" data-anno-id="0" data-anno-label="C1">decitabine</span>  and  <span class="marker" data-anno-id="1" data-anno-label="C1">carboplatin</span>  requires further investigation as a combination treatment for melanoma . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>AnnotatorB:</b>  These results confirm that sequential  <span class="marker" data-anno-id="0" data-anno-label="P1">decitabine</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">carboplatin</span>  requires further investigation as a combination treatment for melanoma . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Sequential decitabine and carboplatin treatment increases the DNA repair protein XPC, increases apoptosis and decreases proliferation in melanoma.</u></h4>Melanoma has two key features, an over-representation of UV-induced mutations and resistance to DNA damaging chemotherapy agents. Both of these features may result from dysfunction of the nucleotide excision repair pathway, in particular the DNA damage detection branch, global genome repair (GGR). The key GGR component XPC does not respond to DNA damage in melanoma, the cause of this lack of response has not been investigated. In this study, we investigated the role of methylation in reduced XPC in melanoma. ### methods To reduce methylation and induce DNA-damage, melanoma cell lines were treated with <b style='color:Tomato;'><i>decitabine</i></b> and <b style='color:Tomato;'><i>carboplatin</i></b>, individually and sequentially. Global DNA methylation levels, XPC mRNA and protein expression and methylation of the XPC promoter were examined. Apoptosis, cell proliferation and senescence were also quantified. XPC siRNA was used to determine that the responses seen were reliant on XPC induction. ### results Treatment with high-dose <b style='color:Tomato;'><i>decitabine</i></b> resulted in global demethylation, including the the shores of the XPC CpG island and significantly increased XPC mRNA expression. Lower, clinically relevant dose of <b style='color:Tomato;'><i>decitabine</i></b> also resulted in global demethylation including the CpG island shores and induced XPC in 50% of cell lines. <b style='color:Tomato;'><i>decitabine</i></b> followed by DNA-damaging <b style='color:Tomato;'><i>carboplatin</i></b> treatment led to significantly higher XPC expression in 75% of melanoma cell lines tested. Combined sequential treatment also resulted in a greater apoptotic response in 75% of cell lines compared to <b style='color:Tomato;'><i>carboplatin</i></b> alone, and significantly slowed cell proliferation, with some melanoma cell lines going into senescence. Inhibiting the increased XPC using siRNA had a small but significant negative effect, indicating that XPC plays a partial role in the response to sequential <b style='color:Tomato;'><i>decitabine</i></b> and <b style='color:Tomato;'><i>carboplatin</i></b>. ### conclusions Demethylation using <b style='color:Tomato;'><i>decitabine</i></b> increased XPC and apoptosis after sequential <b style='color:Tomato;'><i>carboplatin</i></b>. <b style='color:DodgerBlue;'><i>These</i></b> <b style='color:DodgerBlue;'><i>results</i></b> <b style='color:DodgerBlue;'><i>confirm</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>sequential</i></b> <b style='color:MediumOrchid;'><i>decitabine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>requires</i></b> <b style='color:DodgerBlue;'><i>further</i></b> <b style='color:DodgerBlue;'><i>investigation</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>melanoma</i></b> <b style='color:DodgerBlue;'><i>.</i></b></div></div></div></div>

<script>
    var coll = document.getElementsByClassName("collapsible");
    var i;

    for (i = 0; i < coll.length; i++) {
        coll[i].addEventListener("click", function () {
            var content = this.nextElementSibling;
            console.log(content.style)
            if (content.style.display === "block") {
                content.style.display = "none";
            } else {
                content.style.display = "block";
            }
        });
    }

    var dialog = document.getElementById('myFirstDialog');
    document.getElementById('show').onclick = function() {
        dialog.show();
    };
    document.getElementById('hide').onclick = function() {
        dialog.close();
    };
</script>
</body>

</html>
